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Glioblastoma multiforme (GBM) is an aggressive central nervous 
system (CNS) cancer characterized by enhanced tumor cell 
motility, pernicious invasion into the normal brain, extensive 
tumor-induced angiogenesis, and adaptive resistance to current 
therapeutic paradigms.  One of the difficulties associated with 
GBM is the ability of the tumor cells to infiltrate normal CNS 
tissue.  Neurosurgeons can remove the primary tumor mass, but 
  xi 
peripheral cells that are inaccessible will ultimately result in 
a secondary lesion that can lead to death.    
The matrix metalloproteinases (MMP) are well known for 
their abilities to facilitate processes of cellular motility and 
invasion through their clearance of extracellular matrix (ECM).  
A specific member of this family, MMP-1, is not observed in 
normal brain, yet its expression is a common characteristic of 
GBM.  The various causes of MMP-1 expression, and its 
consequences in GBM cells are unknown.   
As such, functional studies were conducted related to the 
induction of MMP-1 expression via another molecule intrinsic to 
GBM, nitric oxide (NO).  The exposure of GBM cell lines to 
nanomolar concentrations of NO produced significant inductions 
of MMP-1 expression and GBM cell motility.  The specific removal 
of MMP-1 with siRNA elicited an abrogation of NO-stimulated 
motility, suggesting a pathological contribution by this enzyme. 
Furthermore, recent accumulating evidence suggests that 
MMP-1 contributes to tumor cell survival and related 
angiogenesis in other cancer settings.  To investigate these 
capabilities in GBM, cell lines were stably engineered to have 
either MMP-1 over-expression or knock-down.  Both tumor 
formation and size were significantly reduced with MMP-1 knock-
down and significantly increased with over-expression.  In a 
  xii 
model of GBM cell-induced angiogenesis, the presence of MMP-1 
contributed to an angiogenic phenotype.  Further angiogenesis 
studies revealed a significant recruitment of host endothelium 
to the tumor interstitium in vivo.  Proteomic studies suggest 
that one mechanism by which MMP-1 could influence angiogenesis 
is through the easement of the anti-angiogenic tissue inhibitor 
of metalloproteinases-4 (TIMP-4), since the removal of MMP-1 
elicits a significant increase in TIMP-4 detection. 
Altogether, these functional data present MMP-1 as a 
promising target for future therapeutic investigation, because 
it is unique to the GBM environment and contributes to key 
overlapping GBM pathologies.  
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I.1  Central Nervous System Neoplasia  
Over eighty years have elapsed since the collaborative work of 
Percival Bailey and Harvey Cushing, A Classification of Tumors 
of the Glioma Group on a Histogenic Basis with a Correlated 
Study of Prognosis, which pioneered the consensus needed to 
better understand and study cancers of the central nervous 
system (CNS, Ferguson and Lesniak, 2005).  Since then the World 
Health Organization (WHO) has published four ‘blue book’ guides 
specifically detailing CNS neoplasia (Louis et al., 2007).  The 
first of these reports (Zülch, 1979) established a basic, widely 
accepted guideline for neuro-pathological grading that allows 
clinicians and scientists to coordinate treatment and research 
efforts across institutions and nations.  Subsequent iterations 
(Kleihues et al., 1993; Kleihues and Cavenee, 2000; Louis et 
al., 2007) of this guide show the evolution in understanding of 
these diseases based upon improving technologies – for example, 
immunohistochemistry, magnetic resonance imaging (MRI), and 
tumor genomes – as well as newly defined, unique tumor types, 
e.g. extraventricular neurocytoma (Louis et al., 2007). 
 Primary CNS tumors are defined as those cancers of 
neuroepithelial origin within the brain and spinal cord, and 
currently have an overall incidence in the United States of 
18.16 per 100,000 person-years (CBTRUS Report, 2009).  This is 
not to be confused with brain metastases from other origins such 
  3 
as lung or breast cancers.  The most frequent singularly 
diagnosed type is meningioma, accounting for 33% of all primary 
CNS tumors.  Fortunately, meningioma is most often a benign 
condition that can be cured with surgical intervention.  Equally 
incident to meningiomas is a broad class known as the gliomas, 
which most commonly arise within the cranial vault.  What is 
most striking about gliomas is that they currently account for 
80% of all CNS malignancies – those cancers that are 
particularly aggressive, becoming terminal illnesses over time 
even with treatment.  By far the most frequent glioma is 
glioblastoma multiforme (GBM), the biology of which is the focus 
of this work.   
By WHO grading standards, GBM is regarded as Grade IV 
astrocytoma.  It is a particularly insidious affliction that, 
after decades of research into the matter, still eludes 
efficacious treatment.  On average in the United States, 
approximately 10,000 new diagnoses of GBM will occur every year, 
and of these fewer than half the individuals will survive an 
additional year.  Less than five percent of those diagnosed with 
GBM will survive to two years (Adamson et al., 2009; Fisher et 
al., 2007).  While malignant glioma accounts for less than two 
percent of adult cancers, it is compelling to discover better 
ways to treat and fight it.  It debilitates its victims in 
staggeringly short course, with profound resistance to current 
  4 
therapies, or otherwise making treatment difficult as it 
progressively assaults the organ of human being, personality, 
emotion, and thought. 
I.2 Grading and Distribution of the Gliomas  
Gliomas are so named because of their resemblances to CNS glial 
cells; thus they are generally distributed as ependymomas, 
oligodendrogliomas, astrocytomas, and tumors of mixed glial 
cytoarchitecture and other characteristics. It was originally 
assumed by many that gliomas possess these features because they 
are risen from late-stage glia by some carcinogenic event(s), 
but concrete epidemiological or etiological data were lacking.  
However, within this decade the identification of cancer stem 
cells has been described within these tumors, and their 
functions and origins are under investigation (Louis, 2006; Suvà 
et al., 2009). 
 Gliomas can be divided between low- and high-grade tumors 
based upon the WHO grades I-IV scale of malignancy.  The lowest, 
grade I, denotes tumors that can be considered benign and only 
require surgical removal for curative effect.  Most ependymomas 
and the rare pilocytic astrocytoma, fall into the Grade I 
category.  When tumors present increased cellularity, indicative 
of more proliferation, and the beginnings of infiltration into 
normal parenchyma, they are classified as grade II; this is one 
  5 
of two currently accepted descriptors for oligodendrogliomas, 
the other being grade III for more aggressive tumors, but there 
is substantial debate regarding the necessity for expanding 
oligodendroglioma categorization.  As with grade I, astrocytomas 
rarely fit into the grade II grouping.  There has been notable 
concern regarding the efficacy of radiologic and 
chemotherapeutic treatments for grade II conditions, as these 
modalities can elicit more discomforting symptoms with little to 
no benefit (Buckner et al., 2007).  Interestingly, the lower 
grade tumors, especially ependymomas and pilocytic astrocytomas, 
are more common in more youthful populations.   
 The high-grade primary CNS tumors are split between grades 
III and IV.  Tumors are staged at grade III when there is clear 
presentation of tumor cell invasion, anaplastic transformation 
(apparent de-differentiation or primitive cell types), and 
extensive proliferation, i.e. mitotic figures.  The aggressive 
oligodendrogliomas and anaplastic astrocytomas are considered 
grade III.  Diagnosis with a grade III neoplasm is usually a 
terminal condition; however grade III oligodendrogliomas have 
the highest extended survival rates notwithstanding substantial 
variability in median survival within histologic sub-types, e.g. 
2-2.5 years for anaplastic astrocytoma and 3-5 years for 
anaplastic oligodendrogliomas (Buckner et al., 2007). 
  6 
 If a grade III tumor does not result in a terminal 
condition it will invariably progress to a grade IV disease.  In 
the context of primary CNS tumors of the developed brain, i.e. 
excluding embryonal tumors and brain metastases, GBM is the only 
grade IV tumor.  It is characterized by a fast course from 
diagnosis to untenable tumor growth, which presents within the 
tumor as core necrotic areas, peripheral endothelial 
hyperplasia, and inaccessible tumor cell infiltrate into normal 
host tissue.  After treatment, a secondary lesion will almost 
always occur which, combined with other associated neurological 
sequelae, will lead to death.  Median survival post-diagnosis 
with GBM is approximately one year (McKinney, 2004; Buckner et 
al., 2007). 
 It is clear that there is a vast array of histologically 
distinct tumor types, and that with the lower grade gliomas and 
meningiomas there is a promising outlook for patient survival 
and quality of life.  Unfortunately, the worst of these cancers, 
GBM, is the second most common primary CNS diagnosis, regardless 
of malignancy.  Furthermore, GBM accounts for a 
disproportionately high share of primary CNS malignancies, and 
has been on the rise since the extensive recording of such data, 
with current figures placing it at 20% of all CNS tumors and 54% 
of diagnosed gliomas (Figure 1.1). 
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Figure 1.1.  Distributions of CNS Neoplasia.  Panel A 
illustrates the distribution of all primary CNS tumors diagnosed 
in the United States for the period 2004-2005 (N=98,990). 
Meningioma is the single most common tumor yet is predominantly 
benign.  However, 80% of primary CNS malignancies are classified 
as various gliomas.  ‘Other’ tumors in Panel A are either 
unclassified histological sub-types or uncommon sub-types with 
lower incidence than can be graphically represented.  Panel B 
illustrates the distribution for all diagnosed gliomas in the 
same period (N=32,279).  Glioblastoma multiforme (GBM) is by far 
the most common at 54%.  ‘Other astrocytoma’ includes astrocytic 
tumors with mixed characteristics, or cases with unique 
characteristics.  ‘Other gliomas’ includes mixed gliomas or 
other rare neuroeptihelial tumors.  This figure was constructed 
using data from the CBTRUS 2009 Report. 
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I.3 Epidemiology and Current Standard of Care for GBM  
The prediction of GBM remains difficult because its complete 
etiology remains unknown.  Compounding this matter is the fact 
that GBM is heterogeneous and arises in two forms: one 
aforementioned from progression of a lower grade condition, 
termed ‘secondary’ GBM; and another noted as ‘primary’ which 
indicates the de novo presentation of the disease.  Over 90% of 
GBM diagnoses are of de novo origin (Ohgaki and Kleihues, 2009).  
The clinical histories for secondary GBM range from 1.4 years, 
if progressed from a grade III condition, to 5.6 years whence 
progressed from grade II.  Illustrative of its short course, 
upwards of 86% of primary GBM patients have a clinical history 
of less than six months; yet mean age at diagnosis with 
secondary GBM is profoundly lower than primary, 45 years versus 
62 years respectively (Ohgaki and Kleihues 2007 & 2009).  
Despite these differences in formation and certain molecular 
heterogeneity described later in this work, GBM as a whole 
converges upon and elicits the same gross pathologies that make 
it difficult to treat: invasion, angiogenesis and resistance to 
apoptosis. 
 Recorded data do indicate that the incidence of GBM is on 
the rise every year.  While the incidence of all primary CNS 
tumors is higher in females as indicated by a current male to 
female ratio of 1:1.22, the reverse is true when examining 
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gliomas and specifically GBM.  Gliomas are significantly more 
common in men at a 1.43:1 ratio, and this carries through with 
GBM at a 1.62:1 ratio for the most current publicly available 
data (CBTRUS, 2009).  Other recent studies analyzing specific 
population sets and slightly older epidemiological data suggest 
that this male to female ratio of GBM incidence could be as high 
as 3:1 for primary GBM (Adamson et al., 2009).  Despite this 
gender disparity, the strongest risk factor for GBM remains age, 
with incidence rate rising to a peak between 75 and 84 years 
(CBTRUS, 2009; Figure 1.2).   
Recently, cellular phone usage has been popularly suggested 
as a predisposition to GBM, having educed special Congressional 
panels investigating the matter in the United States (Hardell et 
al., 2007; Hardell and Carlberg, 2009).  However, the reported 
correlations remain weak due to response bias, and are difficult 
to reconcile in the face of improved technology and the rate at 
which cellular phone usage reached virtual ubiquity over the 
past decades.  Other environmental factors have been proposed 
such as exposure to N-nitroso compounds or second-hand smoke, 
but no causal link has been proven in any case (McKinney, 2004; 
Fisher et al., 2007).  Fewer than 5% of gliomas show familial 
propensity and have been reported to occur coincident with 
inherited malignancy disorders such as neurofibromatosis and Li-
Fraumeni syndrome; but less than 1% of such a population studied 
  11 
 
 
 
 
 
 
Figure 1.2.  Increasing Age as a Predisposition for GBM.  The 
incidence rate of GBM increases exponentially with age to 65-74 
years, and peaks at 75-84 years. This figure was constructed 
using data from the CBTRUS 2009 Report. 
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had GBM (Wrensch et al., 1997).  The only known definitive, 
direct cause of GBM is exposure to ionizing radiation as a 
treatment for children with acute lymphoblastic leukemia (Neglia 
et al., 1991). 
 As mentioned previously, survival and quality of life 
prospects with GBM diagnosis are grim.  Due to the elevated 
intracranial pressure caused by the rapidity of tumor growth, 
initial clinical indications will commonly begin with headaches, 
nausea, and other symptoms of general malaise that become 
progressively worse without alleviation; about one-third of 
victims will suffer seizures (Buckner et al., 2007).  The 
general rule is that approximately 70% of adult tumors will 
occur supratentorially and as such when particularly eloquent 
areas are invaded, partial loss of motor and sensory systems 
will occur associated with the location of the intracranial 
mass.  Up to one-fifth of patients, especially those suffering 
frontal lobe tumors, will also have profound alterations in 
emotional and mental status (Behin et al., 2003; Buckner et al., 
2007).  
 With the combination of these symptoms the physician would 
suspect a brain tumor, and the best method to continue diagnosis 
is with the use of contrast enhanced (gadolinium injection) MRI.  
A halo-like appearance of hyper-intensity is observed with GBM; 
this corresponds to the proliferative periphery of the tumor.  
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Highly invasive tumor cells are found around and outside of the 
halo, and the hypo-intense center represents the necrotic tumor 
mass.  It is important to note that the associated intracranial 
pressure will elicit vasogenic edema that can be detected 
through T2-weighted MRI.  Eventually, removal of the reasonably 
accessible tumor mass and its histopathological analysis will 
confirm GBM with the presence of pseudopallisading cells around 
areas of necrosis, intense tumor associated angiogenesis, and 
the piling of tumor cell masses around circulating blood vessels 
(Holland EC, 2000; Brat et al., 2004; Kaur et al., 2005). 
 The current standard treatment for GBM begins with surgical 
de-bulking of accessible tumor mass soon after initial 
diagnosis, since left untreated the tumor can lead to death 
within three months.  For the six weeks subsequent to surgery, 
the patient receives targeted fractionated irradiation at 
2Gy/day, five times per week.  Concomitant with radiation will 
be temozolomide chemotherapy at 75mg/m2 body surface area/day, 
and for up to six months following radiation 150mg-200mg/m2 body 
surface area five times per month.  Temozolomide is a DNA 
alkylating agent, thus inducing the DNA damage apoptotic 
response in highly proliferative GBM cells (Stupp et al., 2005; 
Jeon et al., 2009).  It has been proven to facilitate the 
extension of median survival time, and is preferred to other 
systemic chemotherapies, such as cisplatin and carmustine 
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(BCNU), because of equivalent effects with milder off-target 
toxicity (Silvani et al., 2009). 
 Overall, one-year post-diagnosis GBM patient survival 
ranges from 17%-30% and two-year survival falls under 5% 
(Adamson et al., 2009).  Surgery plus radiotherapy produces a 
median survival time of 12.1 months, and the inclusion of 
temozolomide only extends this to 14.6 months (Stupp et al., 
2005).  Furthermore, GBM that expresses O6-methylguanine-DNA 
methyltransferase (MGMT) is unresponsive to temozolomide 
treatment, as this enzyme alleviates the primary DNA damaging 
mechanism of that drug (Jacinto and Esteller, 2007).  To improve 
the efficacy of temozolomide usage, agent combinatorial clinical 
trials are underway that involve the focal administration of 
BCNU and/or the ablation of MGMT activity through the 
administration of inactivating substrate O6-benzylguanine, which 
thus far have displayed significant promise (McGirt et al., 
2009; Quinn et al., 2009).  However, a meta-analysis of various 
agent clinical trials over three decades demonstrated that there 
is a two-year survival benefit associated with trial enrollment.  
This has been attributed to selection bias and better access to 
care (Stewart, 2002). 
 Ultimately, GBM patient care will focus on palliative 
management of symptoms.  After standard treatment a second 
lesion will likely occur, and at a site distant from the removed 
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primary mass.  These recurrent tumors clonally adapt to 
treatment paradigms, particularly when DNA damage is involved.  
Younger age, extent of resection, and higher Karnofsky 
Performance Scale score are the best prognoses for longer 
survival.  Regardless, if the individual does not fall victim to 
the increasing intracranial pressure, assuaged to a limited 
extent by corticosteroid treatment, he will eventually succumb 
to the damaging systemic side effects of radio- and 
chemotherapies. 
I.4 Molecular Characteristics of GBM  
It is now widely recognized that GBM is heterogeneous in the 
molecular origins of its pathologies; as mentioned before there 
is rarely a case when a single specific carcinogenic event 
educes gliomagenesis.  Rather this is likely an additive effect 
of multiple tumorigenic transformations that take place at the 
genomic level: either through the loss of tumor suppressor genes 
and function, or through the amplification, over-expression and 
activation of oncogenes (Gu et al., 2009).   
 However, there are some common features among GBMs.  The 
most frequent of these, up to 80%, is loss of heterozygosity 
(LOH) of the long arm of chromosome 10 (10q), thus implying the 
presence of multiple tumor suppressor gene loci across that 
region (Rasheed et al., 2005; Lam-Himlin et al., 2006).  While 
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some primary GBMs display complete LOH, there are rarely 
examples of homozygous deletion of all or parts of chromosome 
10.   Within primary GBM, one of the most well studied of these 
10q tumor suppressors is phosphatase and tensin homolog (PTEN, 
also known as mutated in multiple advance cancers 1 ‘MMAC1’, 
Steck et al., 1997), which is at the 10q23.3 locus and is either 
LOH or mutated in over 30% of GBM (Knobbe and Reifenberger, 
2003).  As the first phosphatase identified as a tumor 
suppressor, PTEN has generated considerable interest.  It is an 
apparent inhibitor of phosphoinositide 3-kinases (PI3K), which 
are cell-signaling transducers active at the plasmalemma.  
Normally, PI3K phosphorylates phosphatidylinositol (4,5)-
bisphospate (PIP2) to form the active phosphatidylinositol (3, 4, 
5)-trisphosphate (PIP3).  This tri-phosphate is required for the 
downstream activation of the AKT-mammalian target of rapamycin 
(mTOR) axis via phosphoinositide-dependent kinases (PDK), 
ultimately inducing the transcription of anti-apoptotic, pro-
survival proteins.  In a non-neoplastic cell PTEN inhibits this 
pathway by de-phosphorylating PIP3 back to the inactive PIP2 
(Simpson and Parsons, 2001).  More recently PTEN dysfunction in 
GBM has been implicated in the resistance to apoptosis by 
protein stabilization of survival factors, i.e. mutant PTEN 
prevents poly-ubiquitination (Panner et al., 2009).  However, 
the deletion or mutation status of PTEN offers no prognostic 
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significance in GBM, which indicates that there are other 
factors vital to the progression of the disease (Lam-Himlin et 
al., 2006). 
 One such factor, the study of which bloomed in the mid-
1990’s because of its association in multiple cancers, is p53.  
With its encoding gene (TP53) located on the short arm of 
chromosome 17, mutation of p53 is more incident than its LOH in 
GBM.  In a healthy cell p53 protein stability is low, because 
Mdm2 binds to and facilitates poly-ubiquitination of p53, 
thereby causing its proteasomal degradation.  When a normal cell 
is exposed to a plethora of stressful stimuli, particularly the 
induction of DNA damage, Mdm2 dysfunction and p53 stabilization 
are coincident.  This activation of p53 leads to the expression 
of cell cycle arrest proteins, especially p21 and halting of the 
cell cycle at the G1/S transition, to allow the stimulation of 
DNA repair or apoptosis (Bögler et al., 1995; Ohgaki and 
Kleihues, 2007).  In effect, p53 is a genome-stress sensitive 
tumor suppressor.  Over 30% of GBMs have been found to express 
mutant p53, most of them secondary (Ohgaki et al., 2004).  While 
mutation of p53 will often cause a loss of function, thereby 
allowing tumor cell growth, gain-of-function mutations have also 
been indicated (Bögler et al., 1995; Oren and Rotter, 2010).  
This is a likely factor confusing whether or not p53 status is a 
valuable prognostic feature and therapeutic target.  Indeed, one 
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major study found that TP53 mutation is favorable to survival 
(Schmidt et al., 2002), yet others have reported the converse or 
insignificance (Simmons et al., 2001; Ohgaki et al., 2004). 
 Over-expression and amplification of certain genes and 
proteins are also fundamental molecular components of GBM.  The 
most richly described of these factors is Endothelial Growth 
Factor Receptor (EGFR), a transmembrane receptor tyrosine kinase 
that is a member of the ErbB family (ErbB1).  Multiple growth 
factors can activate EGFR including: EGF, transforming growth 
factor(TGF)-α, betacellulin and epiregulin.  Once one of these 
ligands is bound, the EGFR monomer can either homodimerize or 
form a heterodimer with p185her2/neu(ErbB2).  This facilitates the 
autophosphorylation of specific tyrosine residues on the C-
terminal end of the EGFR molecules.  The pattern of phospho-
tyrosines serves as an activation anchor for other kinases with 
Src homology2 (SH2) domains, specifically PI3K and mitogen 
activated protein kinases (MAPK), which transduce pro-migratory, 
proliferative, and anti-apoptotic cellular signals (Zhang et 
al., 2007). 
 Amplification of EGFR, either wild type or mutant, is 
observed in approximately 40% of GBM cases, yet interestingly is 
not seen in patients less than 25-years old (Ohgaki et al., 
2004).  Seven predominant, active EGFR mutants have been 
identified, which are for the most part caused by in-frame 
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deletions of the EGFR gene.  By far the most common in GBM is 
named EGFRvIII, found in 50% of amplified tumors (Schwechheimer 
et al., 1995; Rasheed et al., 1999; Adamson et al., 2009).  This 
particular mutant is created by an 801-bp in-frame deletion of 
exons two through seven, and is constitutively active, i.e. does 
not require ligand (Biernat et al., 2004).  Since mutant EGFR 
amplification is unique to the GBM site, and is thought to play 
a vital role in mediating GBM pathology, it is a promising 
therapeutic target.  Indeed, in a trial with non-small-cell lung 
carcinoma (NSCLC) patients (another cancer with unique EGFR 
amplification), a specific inhibitor, gefitinib, showed efficacy 
(Fukuoka et al., 2003).  However similar results with GBM have 
been lacking: while the therapy is tolerable, no objective tumor 
responses were seen with significance across glioma populations 
(Rich et al., 2003; Reardon et al., 2010).  This is likely due 
to at least two important details.  First unlike NSCLC, 
mutations in the kinase domain of EGFR are rare if non-existent 
in glioma (Marie et al., 2005).  Second, it was later 
discovered, in the context of EGFRvIII inhibitors alone (Rich et 
al., 2003), that while EGFRvIII is the most common mutant in 
GBM, its predominance over concomitantly amplified wild type 
EGFR is a rare event (<10%); thus the inhibition of EGFRvIII is 
easily circumvented by tumor cells (Biernat et al., 2004).  An 
intriguing subsequent development was the observation that GBM 
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patients with tumor EGFRvIII and PTEN co-expression responded 
favorably to anti-EGFR treatments (Mellinghoff et al., 2005).  
The latter study underscores the evolving concept of the 
importance of multi-modal, patient specific, molecular targeted 
therapeutics. 
 A great deal of excitement, as well as debate, is currently 
centered upon the inhibition of vascular endothelial growth 
factor (VEGF)-A.  Since the standard treatment paradigm for GBM 
is limited in scope and efficacy, therapeutics useful in 
unrelated cancer conditions are frequently trialed with GBM.  
Bevacizumab is a humanized monoclonal antibody raised against 
VEGF-A, which has offered significant recourse against 
colorectal (Hurwitz et al., 2004), breast (Miller et al., 2005), 
renal (Escudier et al., 2007), and lung (Herbst et al., 2007) 
cancers.  Two recurrent GBM clinical trials testing bevacizumab 
showed substantial improvements in tumor response and six month 
progression free survival (Cohen et al., 2009; Friedman et al., 
2009).  Based upon these findings, where the endpoints were 
assessed by independent radiologist review of MRIs, the USFDA 
fast-tracked the approval of bevacizumab therapy in recurrent 
GBMs non-responsive to other treatments, and its use in newly 
diagnosed tumors is currently under trial.  Despite these 
promising data, credible concerns have been voiced regarding 
this particular therapy.  Unlike the tightly controlled normal 
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blood-brain barrier, GBM vasculature is characteristically 
leaky, and this leakiness is what elicits the classic T1-
weighted GBM images.  Inhibition of VEGF-A potentially 
normalizes and limits this leakiness, therefore offering an 
increased probability for false negative assessments on contrast 
enhanced MRI review.  When evaluated at Phase III this might 
become more apparent, but other indicators within the endpoints 
used for the Phase II trials corroborate favorable effect.  
Another concern is the fact that the normalization of the tumor-
blood barrier could reduce the efficacy of systemically 
delivered chemotherapeutics that rely on the leaky tumor 
vasculature.  Finally available anti-angiogenic therapies, such 
as bevacizumab, are inert with regard to the invasive facet of 
GBM pathology, and have even been hypothesized to enhance 
invasion (Verhoeff et al., 2009; Lucio-Eterovic et al., 2009). 
 While there are some molecular propensities among GBMs, 
none of those that are intensely investigated are present in 
100% of cases, or are entirely unique in the context of the 
local host environment.  In cases where there is some 
exclusivity, e.g. EGFRvIII, the tumor cells because of their 
heterogeneous molecular profile, will often adapt to treatment 
efforts through some other mechanism, e.g. switching from PI3K 
dependence to MAPK (Albert et al., 2009).  The continued 
investigation of molecular targeted therapeutics is desperately 
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needed and many are currently underway, with over 200 clinical 
trials ongoing in the United States as of 2010.  Some of these 
are outlined in Table 1.1 (information provided by the National 
Institutes of Health).  The idea of multi-modal therapies 
tailored to the molecular profiles of individual tumors is 
becoming more favored for particularly aggressive cancers like 
GBM.  However it is still important to discover and investigate 
potential targets that can address multiple GBM pathologies 
(invasion, angiogenesis, and resistance to apoptosis/treatment) 
at the same time.  Based upon this goal, one particular protein 
known as matrix metalloproteinase-1 (MMP-1) is the focus of this 
work.   
I.5  Structure of the Matrix Metalloproteinases  
To date twenty-four distinct proteins are included in a family 
of zinc-dependent endopeptidases known as the matrix 
metalloproteinases (Table 1.2).  These enzymes are well known 
for their abilities to degrade a variety of extracellular matrix 
(ECM) constituents, the first one discovered having been 
characterized as an effective interstitial collagenase (MMP-1; 
Gross and Lapiere 1962).  Over the four decades of study into 
these enzymes it has been discovered that MMPs are far more 
flexible in other activities than ECM degradation and 
remodeling.  The MMPs are also potent protease modulators of  
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Table 1.1.  Agents in Multiple Clinical Trials for GBM.  There 
is a diversity of different drug types and targets, though there 
is a current focus on multiple targets along the PI3K-Akt axis.  
HDAC: histone deacetylases; MGMT: O6-methylguanine-DNA 
methyltransferase.  Not included: AP12009 (small molecule 
inhibitor of TGF-β) and TP-38 (TGF-α/pseudomonas exotoxin 
chimera) were recently concluded in several studies.   
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bioactive molecules and chemotactic positioning.  They are 
integral enzymes in processes of wound healing, cell 
differentiation, development, inflammation, proliferation, 
apoptosis and migration (McCawley and Matrisian, 2001; 
Brinckerhoff and Matrisian, 2002; Chakraborti et al., 2003).  An 
assortment of MMPs has been observed in excess throughout 
varying loci of gliomas which are hypothesized to be integral 
components of microenvironment conducive to progression, 
underlining their importance in pathological states (Fillmore et 
al., 2001; VanMeter et al., 2001).  
Individual MMPs are often referred to by substrate 
specificity (collagenases, gelatinases, stromelysins, 
matrilysins) but the advent of evidence showing that these 
characteristics are overlapping throughout the MMP family led to 
their recognition by protein structure as well (Figure 1.3A).  
All MMPs consist of at least three common domains: a signal 
peptide that directs its translation on the endoplasmic 
reticulum, a pro-domain that maintains the latency of the enzyme 
via the binding of a conserved cysteine to the requisite zinc 
atom, and a catalytic domain which is the enzyme functioning 
portion that also binds the zinc.  Only two of the MMPs (7 & 26) 
consist of just the minimal domains.  Ten MMPs (1, 3, 8, 10, 12, 
13, 19, 20, 27 & 28) have the core domains along with a 
hemopexin domain that is required for protein-protein 
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Table 1.2. The Matrix Metalloproteinases.  There are currently 
twenty-four recognized MMPs.  *MMP-18 is a Xenopus collagenase 
not found in humans.  ξMMP-23 is duplicated in human lineage and 
sometimes referred to as either MMP-23A or MMP-23B (Puente et 
al., 2005).  MMP-19 is often referred to as RASI (rheumatoid 
arthritis synovial inflammation) because of its location 
(Pasternack and Aspenberg, 2009), whilst ‘stromelysin-4’ is an 
oft-used misnomer. 
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Enzyme Type MMP ID Other Name(s) 
Collagenase MMP-1 Interstitial Collagenase; Collagenase-1  
MMP-8 Neutrophil Collagenase; Collagenase-2 
MMP-13 Collagenase-3 
MMP-18* Collagenase-4 
Gelatinases MMP-2 72kDa Gelatinase; Gelatinas- A 
MMP-9 92kDa Gelatinase; Gelatinase-B 
Stromelysins MMP-3 Transin; Stromelysin-1 
MMP-10 Stromelysin-2 
MMP-11 Stromelysin-3 
Matrilysins MMP-7 Matrilysin-1 
MMP-26 Matrilysin-2 
Membrane-Type (Transmembrane) MMP-14 MT1-MMP 
MMP-15 MT2-MMP 
MMP-16 MT3-MMP 
MMP-24 MT5-MMP 
Membrane-Type (GPI Anchored) MMP-17 MT4-MMP 
MMP-25 MT6-MMP 
Other MMP-12 Macrophage Elastase; Metalloelastase 
MMP-19 Stromelysin-4; RASI 
MMP-20 Enamelysin 
MMP-21 
MMP-23! Cysteine Array(CA)-MMP 
MMP-27 
MMP-28 Epilysin 
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interaction and its linker, a hinge domain, which can also 
impart specificity.  With the exception of the cysteine array 
MMP (23) all the other MMPs have the five aforementioned domains 
with further additions.  The classic gelatinases, MMP-2 and -9, 
have fibronectin-like repeats in the catalytic domain required 
for substrate binding, and MMP-9 also has a type V collagen-like 
domain.  In addition, MMP-11 and the membrane-type MMPs (14, 15, 
16, 17, 24, 25) have furin cleavage sites in the pro-domain that 
are important for pro-domain clearance and enzyme activation 
(MMP-23 has a furin cleavage site too).  The membrane-type MMPs 
are further subdivided based on how they are associated with the 
plasmalemma: either through a single transmembrane domain (MMP-
14, 15, 16 & 24) or by a glycosyl phosphatidylinositol (GPI) 
anchor (MMP-17 & 25; McCawley and Matrisian, 2001; Nagase et 
al., 2006). 
I.6  Regulation of the Matrix Metalloproteinases  
Matrix metalloproteinases are initially synthesized as zymogens, 
latent enzymes that require some other event for activation.  
The thiol of a conserved cysteine residue (PRCGXPD) in the pro-
domain maintains the zymogen by binding a zinc atom that is 
chelated by conserved histidines (HEXXHXXGXXH) in the catalytic 
domain.  This effectively blocks the active site with the pro-
domain and prevents water molecules from an interaction that 
allows proteolytic activity.  The enzyme is activated following  
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Figure 1.3. Domain Schemes of the MMPs, and the Cysteine Switch.  
A.  The various MMPs categorized by similar domain construction 
(the arrow denotes that the pro-domain associates with the 
catalytic domain when the enzyme is latent); MMP-7 and -26 
represent the minimal domain set required to be classified as a 
MMP: signal peptide, pro-domain with conserved sequence PRCGXPD, 
and catalytic domain with the conserved sequence HEXXHXXGXXH.  
B.  Diagram of the cysteine switch where under the latent 
zymogen condition the pro-domain (red) coordinates with the 
catalytic site zinc atom (chelated by the three conserved 
histidine residues, H in above catalytic domain sequence) via 
the conserved cysteine thiol (C in conserved pro-domain sequence 
above).  When the pro-domain is attached it prevents hydrolysis 
by obstructing the access of water.  Once the pro-domain is 
removed, water is free to enter and enzyme activity may 
commence. 
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displacement of the cysteine-zinc bond or altogether removal of 
the pro-domain; this mechanism is referred to as the ‘cysteine 
switch’ (Figure 1.3B; Van Wart and Bikedal-Hansen, 1990).  MMP 
activation is multi-factorial by way of direct methods or by 
other MMPs.  For example, plasmin can activate several MMPs 
including MMP-3; MMP-3 in turn can activate MMP-1, -7, -8, -9 
and -13 (Chakraborti et al., 2003; Pasternak and Aspenberg, 
2009).  Interestingly, the activation of MMP-2 can be 
facilitated by TIMP-2, a traditional MMP inhibitor.  Membrane 
Type-1 MMP (MMP-14) associates with TIMP-2 (binds to the MT-1 
catalytic site) and together they localize at the cell membrane.  
Then TIMP-2 also interacts with pro-MMP-2 bringing it into close 
association with another free MT-1 (the MT-1 is understood as a 
dimer by some), which cleaves the pro-domain and switches it to 
the active MMP-2 (Hernandez-Barrantes et al., 2000; Wang et al., 
2000). 
Four groups of physiological MMP inhibitors have been 
identified.  One large inhibitor (772kDa), α2-macroglobulin, 
operates primarily in blood circulation by a bait-trap 
mechanism.  MMPs recognize small portions of α2-macroglobulin and 
cleave them facilitating a conformational change in the 
inhibitor that engulfs the MMP.  The complex binds to its 
receptor (LDL-RP) and is internalized to the cell where 
degradation takes place.  Another inhibitor, reversion inducing 
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cysteine-rich protein with Kazal motifs (RECK), is membrane 
associated through a GPI anchor and thus far has been shown to 
inhibit secretion and substrate binding of MMP-2, -9, and -14.  
Lower than normal expression profiles of RECK have been observed 
in tumor cell lines, suggesting a partial loss of control over 
some MMPs.  Interestingly, RECK knockout animals die pre-natal 
which also insinuates that there may be more biologically vital 
activities involved with RECK than MMPs alone (Oh et al., 2001; 
Baker et al., 2002).  A third set of inhibitors is the secreted 
tissue inhibitors of metalloproteinases (TIMP), a class that 
consists of four distinguishable proteins.  The TIMPs are known 
to broadly inhibit active MMPs by binding the active site 
similarly to normal substrates.   However, the efficacy of MT-
MMP inhibition by TIMP-1 is lacking, and the TIMPs also have 
well known associations with pro-MMPs such as the requirement of 
TIMP-2 for proMMP-2 activation mentioned previously.  Further 
unconventional effects of the TIMPs have been reported for 
features that impact tumor progression such as apoptosis, 
proliferation, adhesion and angiogenesis.  The observations of 
the extensive roles of TIMPs have largely been cell/tissue 
specific and many questions still remain regarding this ever-
growing topic.  The fourth set of inhibitors are the TIMP-like 
molecules which includes a group of proposed, based on binding 
sequence similarity to TIMPs, and experimentally derived 
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inhibitors such as the type I collagen C-proteinase enhancer 
(PCPE) protein (Baker et al., 2002). 
 The MMPs are also transcriptionally regulated, with a great 
deal of similarity among MMP gene promoters.  Their promoters 
can be classified into three general groups (Yan and Boyd, 
2007).  The first classification is the largest (MMP-1, -7, -9, 
-10, -12, -13, -19, -26) and denotes the most complex MMP 
promoters that share in common a TATA box and an activator 
protein(AP)-1 consensus sequence approximately 30bp and 70bp 
respectively upstream of the transcription start site.  Most of 
these promoters also have polyomavirus enhancer activator 3 
(PEA3) sites that act in concert with the proximal AP-1 and 
sometimes other distal AP-1 loci (Benbow and Brinckerhoff 1997).  
The second promoter group (MMP-8, -11, -21) only has the 
proximal TATA box in common, and at least to date have 
comparably straightforward structures.  The final group (MMP-2, 
-14, -28) has neither the proximal TATA box nor AP-1 site (Yan 
et al., 2007).  Unlike the other MMPs, this group is 
constitutively expressed in certain normal tissues (Chakraborti 
et al., 2003).  There are tissue specificities, such as with 
MMP-28 being limited to developing germ cells and MMP-13 being 
restricted to osteoblasts.  However, the details behind this 
specificity remain largely unknown and probably depend on the 
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restricted expression of other transcription factors not yet 
identified to act upon MMP promoters (Yan and Boyd, 2007).   
 The presence of AP-1 sites in the majority of MMP promoters 
implies sensitivity to transduced extracellular signals, 
primarily through the MAPK pathway.  This includes stimulation 
through growth factors (EGF, VEGF, HGF, bFGF), cytokines (INF, 
IL-1β, TNF-α, TGF-β), and ECM sensation by the integrins (DeMali 
et al., 2003; McCready et al., 2005; Yan and Boyd, 2007).  
Furthermore MMP-1, -3, -9, and -11 are profoundly induced by 
nuclear factor-κB (NF-κB) activity.  This is readily apparent in 
MMP-9 as its promoter harbors a traditional NF-κB consensus, 
whereas the others do not (Yan et al., 2001; Vincenti and 
Brinckerhoff, 2002).  The reasons for this are currently under 
investigation and likely involve either non-standard NF-κB 
binding sites in MMP promoters or the transactivation of other 
transcription factors to which these MMPs are downstream. 
 Promoter hypermethylation, which is normally targeted to 
CpG islands, has also been linked to repression of MMP-3 and -9 
transcription (despite their lack of CpG islands), but not MMP-1 
and -2 (Chicoine et al., 2002; Couillard et al., 2006).  Another 
point of control involves chromatin structure, specifically 
through the acetylation and phosphorylation of histones.  
Unfortunately, the epigenetic aspects of MMP regulation are 
poorly understood and require substantial work to establish any 
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further conclusions.  The stability of mRNA is another important 
step in the regulation of MMP expression.  The stabilization of 
MMP-2, -9, and -13 mRNAs by TFG-β has been well established.  At 
least with the MMP-9 transcript, specific areas of the 3’-
untranslated region (UTR) have been identified that interact 
with HuR, an mRNA stabilization factor (Yan and Boyd, 2007). 
 Finally, the presence of various promoter polymorphisms has 
been detailed in several of the MMPs.  Changes in base pair 
sequence can directly influence the binding affinities for 
transcription factors.  Transitions from cytosine (C) to thymine 
(T) at -1306 and guanine (G) to adenine (A) 1576bp upstream in 
the MMP-2 promoter reduce gene transcription (Price et al., 
2001; Harendza et al., 2003).  An A to G substitution in the 
MMP-12 promoter has a similar effect, however a C to T change in 
the MMP-9 promoter (-1562) increases expression (Jormsjö et al., 
2000; Zhang et al., 1999).  The MMP-3 promoter is susceptible to 
the insertion of an extra A at -1171, termed the 6A allele.  
This allele has a propensity to bind inhibitory transcription 
factors over the normal 5A allele (Ye et al., 1999).  Matrix 
metalloproteinase-1 also harbors an insertion, an extra G 1607bp 
upstream of the start site.  This 2G allele introduces an Ets-1 
binding site that acts in concert with a distal AP-1 locus, and 
as yet other unidentified transcription factors, to educe a ras 
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responsive element (RRE) that greatly increases promoter 
activity (Rutter et al., 1998; McCready et al., 2005). 
 
I.7  Matrix Metalloproteinases in Brain Cancer  
The gelatinases have been the most heavily studied MMPs with 
regard to all forms of cancer, especially glioma (Levičar et 
al., 2003; Björklund and Koivunen, 2005).  It has been reported 
that MMP-2 and -9 expression is correlated with increasing 
glioma grade and tumor cell invasion in vitro (Sawaya et al., 
1996; Uhm et al. 1996; Rooprai et al., 1998). As mentioned 
earlier, the MMP-2 promoter is constitutively active and non-
responsive to growth factor stimulation.  Indeed, the protein is 
also constitutively translated and detectable in its pro-form.  
However, its activity is proffered in a non-specific, 
unpredictable manner (Vince et al., 1999).  More recent studies 
have pursued the inhibition of MMP-2 in glioblastoma cultures 
and in vivo modeling to show a reduction in invasion and 
angiogenesis (Kargiotis et al., 2008).  However, later work 
demonstrated that the same inhibition of MMP-2 results in a 
further increase in EGFR in already amplified GBM cell lines and 
xenografts (Gondi et al., 2009).  This could lead to a pro-tumor 
effect that exacerbates GBM pathologies, further diminishing its 
prospect as a good therapeutic target.  On the other hand, MMP-9 
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is inducible by various forms of growth factor signaling that 
are aberrantly controlled in GBM (Levičar et al., 2003; Yan and 
Boyd 2007).  Past studies have reported that MMP-9 inhibition 
reduces GBM cell invasion (Kondraganti et al., 2000).  This is 
rather contrary to observations that MMP-9 is predominant in 
benign tumors, e.g. meningioma (Nakagawa et al., 1994).  
Nevertheless, MMP-9 is detectable in some GBMs to a varying 
degree, yet this expression is neither specific to tumor cells 
nor correlates with proliferative tumor zones (Vince et al., 
1999).  Later work demonstrated that the MMP-9 hemopexin domain 
actually inhibits GBM growth and related angiogenesis 
(Ezhilarasan et al., 2008).  Thus the importance of MMP-9 in 
facilitating GBM pathology has progressively become more 
questionable. 
 The unique MT-MMPs have also been the focus of some study 
in the context of GBM.  Membrane type-1 MMP was found to be 
differentially stimulated in vitro in various malignant glioma 
cell lines, but only following treatment with concanavalin A 
(ConA, Yamamoto et al., 1996).  It was noted in the same study 
that while ConA treatment did not stimulate MMP-2 expression 
(and should not have since MMP-2 is non-responsive to mitogenic 
signal transduction), it did induce gelatinase activity 
concomitant with MT1-MMP production.  These observations were 
recorded before the seminal studies demonstrating that MT1-MMP 
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and TIMP-2 are critical components of MMP-2 activation.  A model 
was proposed whereby MT1-MMP is one of the factors of malignant 
glioma amplification, and it serves as a molecular bridge 
facilitating MMP-2 activity at the invasive membrane front of 
GBM cells (Fillmore et al., 2001).  Subsequent work closely 
examined all of the MT-MMPs with respect to common GBM pathology 
in vitro, namely EGFR signal amplification.  While the mRNA 
levels of all MT-MMPs were higher in cultures with EGFR 
activation, MT1-MMP was by far the most prevalent with upwards 
of a 4-fold induction.  Furthermore, MT1-MMP was the only member 
of the group that had significantly increased protein levels.  
Levels of MMP-2 subsequent to treatment did not change, however 
activity did increase.  The use of EGFR and PI3K inhibitors 
prevented this MT1-MMP expression, and in vitro invasion (Van 
Meter et al., 2004).  Therefore it was found that at least in 
vitro MT1-MMP is an important mediator of EGFR signaling related 
invasion. 
 Matrilysin (MMP-7) has also been examined in patient GBM 
samples, where it was found to be predominantly expressed in 
hypercellular regions.  It is hypothesized to be more important 
for initial tumor establishment and growth rather than invasion 
or metastasis – its precise role in malignant glioma remains to 
be studied (Vince et al., 1999).  The expression of MMP-3 was 
reported in squamous cell carcinoma invasive processes and 
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subsequently examined in malignant glioma cell cultures, where 
its expression was found and could be induced by heat shock 
(Matsuzawa et al., 1996).  However in the same work using 
fluorescence in situ hybridization and later studies 
investigating patient GBM samples, there is little to no MMP-3 
expression (Vince et al., 1999). 
 The MMP-1 promoter work of the Brinckerhoff laboratory 
stimulated a new research front with regard to neoplastic 
processes (Benbow and Brinckerhoff, 1997; Rutter et al., 1998).  
Indeed, MMP-1 was reported to influence tumor cell invasion in a 
melanoma and eventually breast setting (Benbow et al., 1999).  
An early study suggested that in vitro, MMP-1 might be expressed 
by at least one glioma cell line (Nakano et al., 1995).  The 
work of McCready and colleagues (2005) established that in fact 
MMP-1 is expressed at the mRNA, and importantly the mature 
protein level in patient GBM samples.  Their in vitro work did 
show that the 2G promoter enhanced expression, and in patient 
samples the 2G allele was more prevalent.  What is most profound 
from this study is that MMP-1 expression was exclusive to the 
tumors; MMP-1 was not detected in any normal brain controls.  A 
recent study has confirmed that MMP-1 mRNA is increased in a 
larger set of GBM patient biopsies and in some cases with an 
increased gene copy number; and immunohistochemical data have 
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revealed pronounced MMP-1 expression throughout human tumors 
(Hodgson et al., 2009; Anand et al., under review). 
 This accumulating evidence, especially the uniqueness of 
MMP-1 in the context of the local host environment, presents 
this enzyme as a promising target for therapy.  The lack of 
knowledge on MMP-1 in primary CNS neoplasia is largely due in 
part to the concept that it is a collagenase, and its 
traditional substrates are often absent in the CNS milieu.  
However, the idea of traditional substrates requires 
reconsideration owing to concrete data demonstrating that MMP-1 
is an important activator of other MMPs, a potent liberator of 
bio-active molecules from the ECM such as FGF and insulin-like 
growth factor (IGF), and even the effecter of the pro-angiogenic 
G-protein coupled receptor (GPCR) protease activated receptor-1 
(PAR-1; McCawley and Matrisian, 2001; Blackburn and 
Brinckerhoff, 2008). As such factors that can induce the 
expression of MMP-1 in GBM cells and the functional consequences 
are under investigation.  Upon examining the past work of 
others, one finds that an attractive regulatory target of MMP-1 
expression is a small bio-active molecule, nitric oxide (NO), 
produced by another set of enzymes, the NO synthases (NOS), 
which are in part induced in high grade glioma.  The following 
sections introduce NO and its relevance to brain cancer. 
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I.8  Nitric Oxide and the Nitric Oxide Synthases  
The 1998 Nobel Prize for Physiology or Medicine was shared among 
Robert Furchgott, Ferid Murad, and Louis Ignarro for their 
contributions to characterizing NO, formerly known as 
endothelial-derived relaxing factor (EDRF), as it relates to 
blood circulation and the stimulation/maintenance of 
vasodilation.  The abundance of information on the 30Da molecule 
is attributable to many discoveries into its biological roles 
over nearly thirty years.  Originally known as an atmospheric 
pollutant, by 1987 research had shown that NO is an important 
physiological mediator of blood flow, specifically endothelial 
cell dependent vasorelaxation (Nathan and Xie, 1994; Furchgott, 
1999).  In 1988 Moncada and colleagues began publishing findings 
that the conversion of L-arginine to L-citrulline by an 
oxygenase is the primary mechanism of NO production in living 
systems (Palmer et al., 1988).  Soon afterward this enzyme was 
characterized as what is presently known as nitric oxide 
synthase (NOS) and was classified in two distinct categories: 
constitutive (cNOS) which includes sub forms neuronal 
(nNOS/NOS1) and endothelial (eNOS/NOS3); and inducible 
(iNOS/NOS2). 
To date it is known that NO is vital to many different 
physiologic aspects including immune functions, 
neurotransmission, blood pressure, and development in multiple 
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systems.  Nitric oxide signaling to the latter three processes 
is regarded as results of low level NO pulse production via cNOS 
(nNOS and eNOS) which relies on intracellular calcium (Ca2+) 
flux.  Extensive diversity exists in the source stimuli of 
intracellular Ca2+ increase, e.g. hormones, growth factors and 
stress, allowing calmodulin (CaM) formation and binding with 
cNOS.  This binding leads to the production, by NOS, of NO and 
L-citrulline from L-arginine and oxygen in the presence of other 
cofactors, e.g. NADPH, FAD, FMN, heme and tetrahydrobiopterin.  
Once NO is made, the classical method of signaling is through 
the NO-cGMP pathway.  Cytosolic NO induces a conformational 
change and activates soluble guanylate cyclase (sGC) thus 
facilitating the conversion of GTP to cGMP.  Cyclic GMP acts 
broadly as a second messenger and can influence ion channels and 
protein kinase activation, both of which imply significant 
downstream effects (Shinoda and Whittle, 2001; Fukumura et al., 
2006). 
Unlike its counterparts, iNOS is neither found readily in 
action throughout the body, nor is it as wholly dependent on 
Ca2+.  The normal function of the enzyme is the production of NO 
on a massive, sustainable scale (µM) compared to the constitutive 
isoforms (nM).  Induction of iNOS expression by such entities as 
macrophages, Kupffer cells, neutrophils, mast cells, microglia 
and astrocytes is one of many responses to cytokines such as 
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IFN-γ, TNF-α, and IL-1β as well as bacterial endotoxins e.g. 
lipopolysaccharide (LPS).  The resultant cGMP independent 
effects are DNA damage (deamination) induced cytostasis 
(interruption of the cell cycle) and cytotoxicity, inhibition of 
DNA repair mechanisms, depletion of iron, and inhibition of the 
mitochondrial electron transport chain through NO and related 
reactive nitrogen species (nitrite, nitrate, peroxynitrite, 
etc.).  Conversely, other immunomodulatory peptides like TGF-β, 
IL-4 and IL-10 can inhibit iNOS by message interruption and 
decay.  Therefore, iNOS in a normal physiological context is 
commonly seen as the enzyme responsible for NO production as a 
host immune response/defense (Lala and Chakraborty, 2001; 
Fukumura et al., 2006). 
Despite these altogether helpful roles, NO has also arisen 
as a player in pathological processes of several diseases, 
notably cancer.  Nitric oxide and peroxynitrite can act as 
mutagens and have the ability to modify cell cycle control 
mechanisms such as the mutation and/or accumulation of standard 
tumor suppressors like p53 and the activation of other genes.  
Furthermore, the normal signaling mechanisms introduced above 
also hold sway over pathways involved in proliferation, 
apoptosis and cell-matrix/environment interactions, and 
potentially make the difference between tumor regression versus 
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neoplastic transformation, progression and invasion (Choi et 
al., 2001; Fukumura et al., 2006; Lam-Himlin et al., 2006). 
I.9  Nitric Oxide in Brain Cancer  
The first studies focused on NOS in brain tumors were by Cobbs 
and colleagues (1995).  Immunohistochemistry using antibodies 
directed against all three isoforms of NOS as well as NADPHd 
staining (a marker of NOS activity, recall that NADPH is a 
cofactor of the enzymes) and immunoblot analysis of human brain 
tumor homogenates and normal brain for control were compared.  
They found that both nNOS and eNOS were grossly detectable in 
high-grade gliomas (grades III and IV) as opposed to lower grade 
and normal adult brain.  Endothelial NOS was particularly 
concentrated in the vascular endothelial cells of the tumor 
vasculature.  The inducible NOS was not detectable at large in 
most of the samples evaluated, aside from very faint 
immunohistochemical detection in GBM and anaplastic (grade III) 
astrocytomas.  NOS activity was higher in all the tumors 
examined versus control.  This work offered a couple interesting 
conclusions: presentation of the induction of cNOS in brain 
tumors, which was formerly believed to be non-inducible; and the 
localization of NOS and NO activity to tumors, especially 
vascular foci.  The authors posit that NO is responsible for the 
pathology of tumor neovascularization, therefore subsequent 
progression. 
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Bakshi and coworkers (1998) offered the first evidence of 
NOS expression in peritumoral, edematous regions in the brain.  
The investigators were able to confirm earlier findings that 
cNOS was over-expressed in tumor cells, specifically surrounding 
vasculature, and that iNOS was barely present.  Spatially, 
expression was markedly higher in tumor cores and dissipated 
with distance.  They offered other novel insight with the 
observations: that in positive cells NOS was localized to the 
cytoplasm and nucleus, more so to the latter; that nNOS was 
remarkably intense in normal glial cells associated with a few 
tumors; and the presence of iNOS positive immune cells, 
apparently of monocytic lineage, that were invading a number of 
tumors beyond blood vessels.  Work soon after this by another 
group correlated eNOS immunohistochemical labeling in the 
vasculature of astrocytic tumors with grade; labeling became 
more intense with anaplastic astrocytoma and GBM (Iwata et al., 
1999). 
What emerges not just in glioma but cancer conditions in 
general, is that there is a reorganization of NO activity with 
increasing degrees of malignancy; table 1.3 summarizes some of 
the key reports pertaining to primary CNS tumors.  It is clear 
that cNOS expression is correlative with high-grade gliomas, 
thereby overlapping with MMP-1 expression. With regard to NO-
influenced MMP-1 expression there have been at least two  
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Table 1.3.  Nitric Oxide Synthase studies using patient glioma 
samples 
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Study cNOS Observations iNOS observations 
Cobbs et al. 1995 Both increased with 
grade 
Rarely detectable 
Bakshi et al. 1998 Intense cNOS 
immunoreactivity 
associated with GBM 
Not detectable in GBM 
Iwata et al. 1999 eNOS immunoreactivity 
increased with grade 
and intense in GBM 
Not assessed 
Ludwig et al. 2000 cNOS most detectable 
in GBM and associated 
endothelial cells, eNOS 
correlated with VEGF-
R expression 
Low Detection, 
primarily immune cells 
in nearby vasculature 
Kao et al. 2003 Not assessed Greater in glioma, 
particularly lower 
grades and in apoptotic 
areas 
Broholm et al. 2003 nNOS increased with 
grade, eNOS mostly in 
endothelial cells 
Sporadic detection in 
all tumors 
Erdamar et al. 2006 Overexpression of 
eNOS and VEGF 
correlated with 
increasing grade.  
nNOS not assessed 
Not assessed 
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reports.  Yoshida et al. (2001) observed an induction of MMP-1 
mRNA in cervical fibroblasts treated with DETA-NO and SNP (NO 
donor molecules).  Ishii and coworkers (2002) demonstrated in 
human melanoma cell lines an increase of MMP-1 mRNA after 
exposure to SNAP (another NO donor) and transient transfection 
of an active iNOS gene.  In addition, MMP-1 promoter activity 
was increased as observed with a luciferase promoter construct.  
By promoter deletion analysis and point mutations they were also 
able to define AP-1 and ETS binding regions that were vital for 
the NO induced MMP-1 expression.  Further experiments using 
selective MAPK pathway inhibitors led to the conclusion that 
this effect was mediated through the ERK and p38 pathways. 
I.10  Hypothesis and Thesis Objectives  
Despite over three decades of research into methods to address 
the hallmark pathologies that make GBM such a devastating 
cancer, there still remains a paucity of effective treatment 
options that can considerably extend the survival of GBM 
victims.  It is becoming more apparent that addressing GBM will 
require specific targets that are known to influence invasion, 
tumor related angiogenesis, resistance to apoptosis, and 
proliferation.  It is logical to pursue the MMPs as a potential 
target because of their well-known abilities to clear ECM, and 
release bio-active molecules. 
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 Based upon prior work showing that MMP-1 is unique to GBM 
in the context of the local host environment the central 
hypothesis underlying the following described studies is that 
the expression of MMP-1 enhances glioblastoma cell 
tumorigenicity. 
  The first portion of this work (Chapter 2) studied the 
potential interaction between NO and MMP-1.  As mentioned above, 
the enzymes that produce NO, especially the nanomolar producing 
constitutive isoforms, are enhanced in higher-grade tumors.  
This is coincident with MMP-1 expression.  Work in other systems 
has presented compelling evidence that NO can indirectly induce 
the expression of MMP-1 in a pathological setting, yet this has 
never been demonstrated in the context of GBM.  Furthermore, a 
plethora of pharmacologic inhibitors of NOS are available for 
use.  Therefore in vitro studies were performed using NO donor 
molecules at a concentration reflective of NO production by 
cNOS, with the aims of observing enhancements in MMP-1 mRNA and 
protein expression levels, and induction of GBM cell motility. 
 Nitric oxide was found to enhance the expression of MMP-1 
at both the mRNA and secreted protein levels in GBM cell lines.  
Motility was also induced in an MMP-1 dependent manner as 
determined with siRNA-mediated inhibition of MMP-1.  Chapter 3 
entails further examination into the tumorigenic potential of 
MMP-1.  Glioblastoma cell lines were manipulated to either 
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stably over-express or knock-down MMP-1 protein production.  The 
central aims of these studies were to assess tumor incidence, 
growth, and angiogenic potential in vivo.  In vitro assays were 
also carried out modeling angiogenesis, as well as proteomic 
arrays examining possible coincident or downstream players in 
MMP-1 mediated GBM pathologies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  53 
 
 
 
 
 
Chapter 2 
 
 
 
 
Induction of matrix metalloproteinase-1 and 
glioma cell motility by nitric oxide. 
(Published in a condensed form in the Journal of Neuro-oncology 
96(2):201-9) 
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II.1  Abstract  
High-grade gliomas invariably recur due in large part to tumor 
cells permeating brain in an inaccessible, diffuse manner.  
Previous work demonstrates that the expression of matrix 
metalloproteinases (MMP) contributes to this characteristic.  
Not only can MMPs assist a cell in traversing its environment by 
clearing extracellular matrix molecules, but they can also 
impact non-traditional downstream signals that affect a cell’s 
ability to interact and respond to its surroundings.  
Contributions to the induction of MMP expression and functional 
significance in glioma are still under investigation.  Evidence 
in other cancer settings indicates that nitric oxide (NO) may 
play a role in tumor/cell progression and that NO can influence 
MMP production.  Matrix metalloproteinase-1 (MMP-1), also known 
as interstitial collagenase, and the constitutive nitric oxide 
synthases (NOS) have been shown to be over-expressed in high-
grade gliomas.  The following study investigated the potential 
involvements of NO with regard to MMP-1 and functional glioma 
cell movement.  With the treatment of a clinically relevant NO 
donor, sodium nitroprusside (SNP) there was significant 
induction of MMP-1 mRNA, secreted MMP-1 protein and motility of 
glioma cell lines within 48 hours.  RNA inhibition of MMP-1 
through transient transfection of three MMP-1 specific siRNAs 
revealed a marked abrogation of the NO-mediated induction of 
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motility.  In addition application of the NOS inhibitor Nω-Nitro-
L-arginine methyl ester (L-NAME) impaired movement of glioma 
cells.  These data provide evidence for a regulatory axis of 
high-grade glioma cell movement from NO through MMP-1, with NOS 
inhibitor results showing promise for future pharmacologic 
investigation. 
 
II.2  Introduction  
A hallmark difficulty of high-grade glioma treatment is 
addressing the diffuse nature of these tumors.  Glioma cells 
invade the normal brain parenchyma intimately making complete 
surgical resection impossible to achieve.  Unfortunately the 
efficacy of various treatment modalities with high-grade gliomas 
is most often marginal with primary care focused on palliative 
management (Louis et al., 2002; Krex et al., 2007; Buckner et 
al., 2007).  Studies have revealed that specific members of a 
class of extracellular matrix (ECM) degrading enzymes known as 
the matrix metalloproteinases (MMP) are partially responsible 
for the increased invasive capacity of high-grade gliomas 
(Nakano et al., 1995; Fillmore et al., 2001; VanMeter et al., 
2001; Stojic et al., 2008).  MMPs and their downstream signals 
are vital components of cell-ECM interaction, growth, 
communication and survival (McCawley and Matrisian, 2001).  
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Specifically, it has been demonstrated that MMP-1, also known as 
interstitial collagenase, is consistently over-expressed at the 
mRNA and protein levels in high grade astrocytomas while not 
found in normal brain (McCready et al., 2005).   
We posit that the small bio-messenger nitric oxide (NO) may 
be strongly associated with these changes in MMP-1 expression.  
Previous findings in other systems indicate that NO can indeed 
influence the MMP-1 promoter and ultimately expression of the 
complete protein (Yoshida et al., 2001; Ishii et al., 2002; Choe 
et al., 2003).  Furthermore, there is a discoordinate regulation 
of the enzymes that endogenously produce NO, the nitric oxide 
synthases (NOS), in primary CNS tumors, whereby there is an 
apparent up-regulation of constitutive NOS isozymes and 
decreases of the inducible NOS (Chapter 1, Table 1.3).  Nitric 
oxide can have paradoxical effects on the cell where on one hand 
it can confer resistance to apoptosis and enhance proliferation, 
whereas it can also be toxic through induction of DNA damage 
responses and inhibition of electron transport (Fukumura et al., 
2006; Lam-Himlin et al., 2006; Ridnour et al., 2006).  The 
latter of these issues are likely a result of micromolar, 
inducible NO production which is most often a host immune 
response, while the former is attributable to the constitutive 
NO synthases found in excess in high grade tumors. 
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In the following study the theory of an axis of glioma 
invasion and cell movement in vitro involving NO and MMP-1 was 
pursued. Nitric oxide donors, compounds that shed NO in 
solution, were applied to established malignant glioma cell 
cultures and subsequent changes in MMP-1 mRNA, protein 
expression, motility and cell viability were examined.  Observed 
was a marked increase in both MMP-1 message and overall protein 
in glioma cells treated with NO.  There was also significant 
enhancement of glioma cells’ abilities to traverse and penetrate 
through a membrane barrier assay at lower NO levels.  Viability 
of these cells was not affected by constitutive-like NO 
concentrations within the exposure periods used for assessment 
of cell movement.  However, high doses of donors, reflective of 
inducible NO concentrations swiftly ablated the survival of 
glioma cells.  Cells transfected with siRNA to inhibit MMP-1 
protein production resulted in the impairment of NO-induced cell 
movement.  In addition the NOS inhibitor L-NAME educed a 
striking reduction in glioma motility.  These data suggest that 
there is a regulatory relationship between NO and MMP-1 in 
malignant glioma cells and that these factors support their 
highly motile and invasive nature. 
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II.3  Materials and Methods  
Cell Culture 
T98G or U87MG cells obtained from American Type Culture 
Collection (ATCC, Manassas, VA, USA) were monolayer cultured in 
Dulbecco’s Modified Eagle Medium (DMEM Invitrogen, Carlsbad, CA, 
USA) with 4.5g/L D-glucose supplemented to 1% 
penicillin/streptomycin (Invitrogen) and 10% FBS (Gemini Bio-
Products, West Sacramento, CA, USA). Cultures were maintained in 
a 37oC, 5% CO2 atmosphere. Cells were passed by enzymatic means 
of a 0.25% trypsin/EDTA solution (Invitrogen), then plated in at 
least six replicates per condition and allowed to acclimate for 
24 hours, upon when NO donor treatment was started.  Either 
sodium nitroprusside (SNP) or S-nitrosoglutathione (GSNO) as 
donors or Nω-Nitro-L-arginine methyl ester (L-NAME), a NOS 
inhibitor, was applied by dissolution in normal medium or medium 
without serum.  For RNA experiments, U-87MG cells were cultured 
in T-25 flasks (Nunc, Langenselbold, Germany) containing 
complete medium.  The complete medium was replaced with media 
containing the different NO related compounds and allowed to 
incubate for 24h.  U-87MG and T98G cells were cultured in 6-well 
plates (Corning, Lowell, MA, USA) with a density of 200,000 
cells per well for the protein analyses, and grown in white-
walled 96-well plates (Corning) with an initial density of 2,000 
cells per well for viability assays. 
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RNA Isolation and Analysis 
Total RNA was isolated from treated and control cells using 
TRIzol reagent (Invitrogen) at a ratio of 1mL TRIzol to 10cm2 
plating surface. An Ultrospec 2000 UV/Visible spectrophotometer 
(GE Healthcare, Buckinghamshire, UK) set for reading absorbance 
at 260nm and 280nm was used to determine RNA concentration and 
quality. Samples were treated with one unit of RQ1 RNase-Free 
DNase (Promega, Madison, WI, USA) per microgram of RNA at 37oC 
for thirty minutes.  Then a DNase stop solution was added 
equivalent to 10% of the sample volume and incubated for ten 
minutes at 65oC.  TaqMan Gene Expression Assays (Applied 
Biosystems, Foster City, CA, USA) for MMP-1 and Cyclophilin A 
were performed in at least five replicates per sample, including 
a human total RNA reference (Stratagene, La Jolla, CA, USA), at 
the Nucleic Acids Research Facilities (Virginia Commonwealth 
University, Richmond, VA, USA) using an ABI 7900 TaqMan Sequence 
Detector (Applied Biosystems).  The mean quantity of Cyclophilin 
A mRNA was used as a loading reference to compare MMP-1 quantity 
among samples.   
Protein Isolation and Analysis 
Conditioned media were aspirated and centrifuged 1000xg for 5 
minutes to separate debris.  Lysates were obtained by cold 
extraction with RIPA buffer (50mM Tris-HCl, 150mM NaCl, 1% 
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sodium deoxycholate, 1% NP-40, 0.5% SDS) containing protease 
inhibitors (EMD Biosciences, Darmstadt, Germany).  RIPA buffer 
was added to each sample well and incubated at 4oC with vigorous 
agitation for five minutes.  Then residual lysates were scraped 
free from the well and passed thrice through a 22ga needle to 
shear DNA.  The mixture was centrifuged 14000xg for 10 minutes 
to separate the cytosolic and membrane fractions – the cytosolic 
fraction was analyzed.  Protein concentrations were determined 
through the DC Protein Assay (Bio-Rad, Hercules, CA, USA). 
Conditioned media containing 4μg or lysates containing 25 μg of 
protein were examined by immunoblot. Samples were resolved by 
SDS-PAGE in 4%-12% Bis-Tris gels (Invitrogen) then transferred 
to 0.45μm pore nitrocellulose membranes (Invitrogen).  Membranes 
were blocked with tris-buffered saline Tween-20 (TBST), 5% non-
fat dry milk for one hour at ambient temperature, then primary 
probed with either mouse monoclonal α-MMP-1 (MAB901 R & D 
Systems, Minneapolis, MN, USA) in conditioned media and lysates 
or rabbit polyclonal α-Cyclophilin A (07-313 Millipore Billerica, 
MA, USA) for lysates overnight at 4oC.  This was followed by TBST 
rinses (five times four minutes) and secondary application of 
affinity purified, peroxidase conjugated goat α-mouse (610-1302 
for MMP-1) or α-rabbit (611-1302 for Cyclophilin A) IgG 
antibodies (Rockland Immunochemicals, Gilbertsville, PA, USA) 
for ninety minutes at ambient temperature.  Immunoreactivity was 
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detected through Enhanced Chemiluminescence Reagents (ECL, GE 
Healthcare) with subsequent exposure to autoradiographic film 
(Denville Scientific, Metuchen, NJ, USA).  Densitometric 
analysis of immunoreactivity was carried out using ImageJ (NIH). 
Cell Viability Assays 
 The CellTiter-Glo® Luminescent Cell Viability Assay (Promega) 
was utilized to assess the number of cells present after NO 
donor treatment. 2,000 cells were seeded into each well of 
white-walled 96-well plates (Corning), with six replicates per 
condition.  After one day of allowing the cells to attach and 
acclimate, complete media were gently aspirated and replaced 
with media +/- compound and serum.  This assay involved 
incubating complete cultures including media at chosen end 
points (one to six days) 1:1 volumetrically with a proprietary 
lysis reagent that produces a luminescent signal directly 
proportional to the amount of ATP present.  A standard curve of 
known ATP concentrations was analyzed to estimate [ATP] from 
each culture condition (at least six replicates each).  Readings 
were obtained using a Fluostar Optima plate reader (BMG Labtech, 
Durham, NC, USA) and the provided software for estimation of ATP 
concentration.  
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Membrane Motility Assays 
The ChemoTx® System (Neuroprobe, Gaithersburg, MD, USA) was used 
to gauge changes in movement by the glioma cells.  A 96-well 
microplate format with 8μm pore polycarbonate membranes was 
utilized. The wells of the provided 96-well microplate were 
filled with 312.5µL complete medium containing 0-1mM of SNP, 
GSNO, or L-NAME.  Fifty microliters of suspensions of 400,000 
cells/mL of NO donor containing media were distributed per test 
site (membrane area above a well).  Membranes were placed over 
the microplates and cells were allowed to settle and move 
through the membrane for 24h or 48h.  At the desired time point, 
the membrane was removed and 200µL of media discarded from each 
well of the plate.  The aforementioned ATP viability assay was 
applied to the well as a measure of cells that moved through and 
detached below the membrane. 
Transient Transfection of MMP-1 siRNA 
T98G cells were transfected with Silencer Select pre-designed 
siRNAs against MMP-1: s8847 sense, GGAAUUCUUUGGGCUGAAAtt; s8848, 
sense CUAGAACUGUGAAGCAUAUtt and s8849 sense, 
CCAACAAUUUCAGAGAGUAtt (Ambion, Austin, TX, USA).  Cells were 
seeded at a density of 200,000 cells per well in 6-well plates 
and allowed to settle in complete DMEM for one day.  The day 
subsequent to plating, transfection mixtures were produced for 
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each condition: normal (no transfection reagent, no siRNA), 
reagent only, scrambled siRNA, and siRNA, by first aliquotting a 
volume of 0% FBS Opti-MEM I Reduced Serum Medium (Invitrogen) 
equivalent to 100µL per replicate.  Oligofectamine transfection 
reagent was added to reach 2% of the transfection mixture 
volume; tubes were briefly agitated and allowed to incubate for 
five minutes at ambient temperature.  Complexes of siRNA at a 
20µM stock concentration were added to the transfection mixtures 
to reach a final concentration of 15nM, i.e. 1.875µL per 2.5mL of 
final medium volume in one well of a 6-well plate.  The mixtures 
were briefly agitated and incubated at ambient temperature for 
twenty minutes.  During the incubation, normal media were 
removed and the cultures were gently rinsed with 0% FBS Opti-MEM 
I.  500µL Opti-MEM I supplemented to 2% FBS was aliquotted to 
each well in preparation for transfection.  After the twenty-
minute incubation 104µL of transfection mixtures were added to 
respective wells and the plates were incubated in this solution 
with gentle agitation for four hours at 37oC.  At the end of this 
final incubation the media volumes were brought to 2.5mL with 
15% FBS Opti-MEM I.  Cells were assayed for protein 72h and 
membrane invasion 96h post-transfection. 
Statistical Analyses 
JMP 7 software (SAS, Cary, NC) was utilized for the analysis of 
data.  Cell viability, RNA and protein densitometric data were 
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compared using two-tailed Student’s t-tests for differences 
among experimental treatment groups and relevant controls.  
Membrane assay data were tested using one-way ANOVA.  If 
variances were equal, then groups were subsequently compared 
using Tukey’s honest significant differences test (HSD).  
Differences between experimental groups and relevant controls 
were deemed significant if p<0.05. 
 
II.4  Results  
A Constitutive Concentration of Nitric Oxide Donor Induces MMP-1 
mRNA in U-87MG Cells 
This study sought to understand potential influences of NO upon 
MMP-1 in glioma cell lines.  It began by employing a common NO 
donor Sodium Nitroprusside (SNP).  U-87MG cells were cultured 
under normal conditions (complete medium) until the beginning of 
SNP treatment.  Complete media were removed and replaced with 
serum free medium with SNP at 100µM.  Considering previous 
literature regarding the preponderance of the constitutive 
Nitric Oxide Synthases (nNOS and eNOS) in high-grade gliomas, 
and taking into account that µM NO is indeed cytotoxic, 
physiologically relevant donor concentrations were applied.  
Accordingly, 100µM SNP is approximately equivalent to nanomolar 
ranges of NO (Jaffrey and Snyder, 2001; Ederli et al., 2009). 
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 Total RNA was collected 24h following the media 
replacement, and subjected to real time PCR analysis by the 
TaqMan® method at the VCU Nucleic Acids Research Facilities with 
probes specific for MMP-1 (CCA GGT ATT TCT GGA CTA AGT CCA CAT 
CTT GC) and cyclophilin A (CACCACATGCTTGCCATCCAACCA) as a 
reference control.  The ratio of MMP-1 to cyclophilin A was 
significantly greater from cells treated with the NO donor 
(p<0.001 [Figure 2.1A]).  This difference was accounted for by a 
14.7-fold increase in MMP-1 mRNA relative to cyclophilin A.  To 
our knowledge this is a novel observation among glioma cell 
lines, while in agreement with an effect observed recently in 
human cervical fibroblasts and melanoma cells (Yoshida et al., 
2001; Ishii et al., 2002). 
MMP-1 Protein Increases with Sodium Nitroprusside Treatment 
Next were assayed conditioned media from glioma cell cultures 
treated with SNP to determine if the observations of increased 
MMP-1 transcript in its [SNP] presence were mirrored at the 
secreted protein level.  Serum free, conditioned media from U-
87MG and T98G cells treated with 100µM SNP were collected 24h 
following initial exposure to SNP.  After analysis for protein 
content (DC Protein Assay, Bio-Rad), conditioned media were 
equally loaded and resolved by SDS-PAGE under reducing 
conditions followed by transfer to nitrocellulose membranes and 
immunoblotting for MMP-1 using a mouse monoclonal anti-human 
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MMP-1 antibody (R & D Systems).  U-87MG cells normally have a 
low to undetectable level of MMP-1 protein expression and 
secretion.  However, when exposed to 100µM SNP for 24h, U-87MG 
conditioned media displayed a marked induction of MMP-1 protein 
compared to untreated controls (Figure 2.1B).  Indeed, MMP-1 was 
scantly detectable in 24h U-87MG controls, with SNP treatment 
groups having on average 3.3 times more MMP-1 (Figure 2.1C).  An 
increase of MMP-1 was also observed with conditioned media from 
T98G cells (Figure 2.1B & C) treated with 100µM SNP.  Unlike U-
87MG, T98G cells express a basal level of MMP-1 protein that is 
readily detectable in untreated cells’ conditioned media and 
lysates.  Thus we chose to pursue this cell line with subsequent 
siRNA optimization experiments and functional assays for cell 
motility.  
Increase in Glioma Cell Movement Following NO Donor Treatment 
It has been previously reported that MMP-1 is expressed in high-
grade gliomas, yet not in normal brain (Nakano et al., 1995; 
McCready et al., 2005; Stojic et al., 2008).  MMPs theoretically 
facilitate the movement of the cells through the extracellular 
matrix as well as having other non-traditional targets, e.g. 
MMP-1 is capable of cleaving IFG-BP thereby releasing a potent 
growth factor Nakano et al., 1995). Having addressed that NO 
donor increases MMP-1 message and protein at a constitutive-type  
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Figure 2.1. NO Induction of MMP-1 A: MMP-1 mRNA amplified from U-87 
MG cells treated with 100µM SNP for 24h; Quantities of MMP-1 were 
normalized to those of Cyclophilin A amplified in the same samples.  
Control samples received no SNP treatment.  B:  Representative 
immunoblots for MMP-1 in the conditioned media of U-87MG and T98G 
cells treated with 100µM SNP for 24h.  C: Densitometric analyses of 
MMP-1 immunoreactivity across four separate experiments.  
*,p<0.001; +, p<0.05. 
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concentration, we pursued the possibility that the migration of 
the cells may be a downstream constituent of NO.  U-87MG or T98G 
cells were plated at equal densities onto 8µm pore diameter 
polycarbonate membranes.  Media, both above and below the 
membranes, contained NO donor and cells were allowed to migrate 
for 24h to 48h after which the bottom well was measured with an 
ATP-based viability assay for cells that successfully crossed 
the barrier.  Both U-87MG and T98G cells in the presence of low 
dose SNP (100µM) more successfully relocated to the lower chamber 
within 48h.  U-87MG cells only displayed a modest, though 
significant, increase of 21.6% (Figure 2.2).  On the other hand, 
T98G cells revealed a 400% or greater induction of movement with 
100µM SNP (Figure 2.3A & B). We performed the same assessment 
using a physiological NO donor, GSNO, at donor concentrations 
equivalent to those used for SNP.  100µM GSNO revealed a 
significant increase of cells across the membrane of 35.6% 
(p<0.001, Figure 2.4A) in T98G cells alone.  A high dose of 
either donor (1mM) revealed a knock down of at least 80% in both 
U-87MG and T98G relevant to this assay (p<0.001, U-87MG: Figure 
2.2; T98G: Figure 2.4). 
The reaction of these cells in this assay in response to L-
NAME was also tested.  Treatment with the NOS inhibitor, 
regardless of concentration, led to migratory impediment greater 
than 40% compared to control (p<0.001, [Fig. 2-3C]) with the 
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Figure 2.2.  Membrane motility assay of U-87MG cells exposed to 
varying concentrations of the NO donor SNP.  There was a modest 
but significant increase in motility with 100µM SNP, which 
reflects constitutive-type NOS production.  The apparent 
motility of U-87MG cells in the presence of 1mM SNP was 
substantially reduced.  *p<0.001   
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Figure 2.3.  Membrane motility assays of T98G glioma cells in the 
presence of SNP and a NOS inhibitor, L-NAME.  A & B: T98G cells 
subjected to 100µM SNP for 24h (A) or 48h (B) displayed an 
induction of cell motility versus untreated controls.  C: T98G 
cells with the arginine analog NOS inhibitor L-NAME at all doses 
showed significantly decreased motility with the maximal effect at 
1mM.  *, p<0.001. 
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Figure 2.4.  T98G membrane motility assays with high dose NO 
donor.  A. Membrane motility assays of T98G cells exposed to 
varying concentrations of the physiological NO donor GSNO.  
Motility was significantly increased with 100µM GSNO and reduced 
with 1mM.  B.  Membrane motility assays of T98G cells 
demonstrating the apparent significant decrease in motility with 
1mM SNP. *p<0.001 
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maximal impairment of 53.1% at 1mM.  These data implicate the 
endogenous production of NO as an important factor contributing 
to glioma cell movement. 
To address the hypothesis that the previous observations 
could be due to changes in viability/proliferation with NO 
exposure rather than cell movement, the same ATP based viability 
assays were performed over 5 days in the presence of NO donors 
in normal culture conditions.  Lower concentrations (1µM and 
100µM) of NO donor (either SNP or GSNO) did not elicit 
significant changes in glioma cell viability compared to 
untreated controls.  However, with 1mM SNP there was cell death 
within hours of initial exposure and by the first day culture 
viability of glioma cells fell approximately 80% (p<0.001 
[Figure 2.5A & Figure 2.6]) compared to control, followed by 
undetectable levels of ATP by the fifth day. 
Finally, having noted a marked decrease in motility with 
the NOS inhibitor L-NAME, glioma cell viability in its presence 
was assessed to exclude compound related mortality as the cause 
for those observations.  There were no significant changes in 
viability among treatment groups across times of exposure when 
motility assays were also performed, but by the fifth day there 
were modest yet significant reductions in viability with ≥100µM 
(Figure 2.5B). 
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Figure 2.5.  ATP viability assays of T98G and U-87MG cells  A.  
Viability in the presence of NO donor (either SNP or GSNO) over 
time at varying concentrations.  Constitutive-like donor 
concentrations ≤100µM did not significantly affect viability, 
however 1mM donor inclusion reduced culture viability 
substantially (p<0.001).  B.  Viability in the presence of the 
NOS inhibitor L-NAME over time at varying concentrations.  By 
Day 5, there were modest yet significant reductions in cultures 
treated with ≥100µM L-NAME (p<0.001). 
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Figure 2.6.  Phase contrast microscopy of U-87MG cells over five 
days in the presence of SNP at varying concentrations (100X 
magnification).  The X-axis represents time points in culture 
with SNP increasing from left to right, and the Y-axis displays 
different concentrations of SNP increasing from top to bottom.  
It can be seen within hours (bottom left corner) that treatment 
with the 1mM dose of NO donor is cytotoxic, while all other 
treatments appear grossly similar to the control (no treament – 
top row). 
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Transient Inhibition of MMP-1 Protein in Glioma Cells via siRNA 
Blunts the NO Induction of Glioma Cell Movement 
Next it was sought to inhibit MMP-1 to determine if it had an 
impact on the apparent NO stimulated migration, as both MMP-1 
mRNA and protein are concomitantly increased with NO donor 
presence.  First, several different pre-designed siRNAs for MMP-
1 were tested: s8847, s8848 and s8849 (Silencer Select, Ambion, 
see II.3 Methods for sequences).  T98G cells were chosen as an 
initial target since regardless of NO input or serum condition 
they produce a readily detectable basal level of MMP-1 protein.  
Oligofectamine transfection of all siRNAs to a final 
concentration of 15nM reduced MMP-1 immunodetection at least 50% 
(Figure 2.7).  The s8849 siRNA provided the strongest knock down 
at over 95% compared to normal (untransfected) T98G control 
(Figure 2.7A & C).  The three siRNAs were also pooled, each 
contributing equally to the final RNA concentration in culture, 
and with combination a similar MMP-1 protein inhibition was 
observed (Figure 2.7B).  Transfected T98G cells were subjected 
to the aforementioned membrane assay in the presence or absence 
of 100µM SNP for 48h, corresponding to 96h post-transfection.  
The inhibition of MMP-1 protein production did not prohibit 
basal movement.  Indeed, regardless of siRNA condition it was 
observed that the transfection procedure affects the glioma 
cells by mildly inducing movement. 
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Figure 2.7.  Transient transfection of MMP-1 siRNA into T98G 
cells at a final concentration of 15nM.  A: Representative blot 
of T98G lysates from: N, Normal (untransfected control); B, 
transfection buffer (Oligofectamine); Scr, scrambled; or three 
different siRNAs specific for MMP-1, s8847, s8848, s8849.  The 
immunoreactive banding at 52kDa corresponds to MMP-1 while the 
detection at 17kDa is the loading control, cyclophilin A.  B:  
Representative blot of T98G lysates where the three siRNAs were 
equally pooled.  C: Densitometric ratios of MMP-1:Cyclophilin A  
immunoreactivity from the blot in A quantifying siRNA mediated 
knockdown of MMP-1. 
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All groups given SNP were significantly more motile than normal 
T98G.  However, when the differences among each group and 
relevant controls were calculated, representing the extent of 
NO-mediated induction, it was observed that the NO induction of 
movement was abrogated at least 60% in cells that received 
siMMP-1 (p<0.001, [Figure 2.8]), and that this effect was 
significantly less than either transfection control (p<0.05). 
 
II.5  Discussion  
The present study demonstrates a role for nitric oxide in the 
motility of high-grade, malignant gliomas.  A glioma cell’s 
capacity for movement is essential to the insidious, invasive 
nature of these tumors.  Herein it was shown that with a NO 
donor concentration reflective of NO production by the 
constitutive nitric oxide synthases there is a clear induction 
of both MMP-1 mRNA and secreted protein from glioma cells in 
vitro.  These observations alone are important to consider 
because of previous evidence presenting that high-grade gliomas 
over-express NOS and MMP-1, particularly since MMP-1 is not 
found in normal brain parenchyma (McCready et al., 2005; 
Introduction Table 3).  These experiments delineate a 
potentially strong link between both enzymes, as they appear 
discoordinately regulated between high-grade, malignant gliomas 
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Figure 2.8.   Abrogation of NO-mediated induction of glioma cell 
movement.  When examining the differences between +/- SNP in 
each group, siMMP-1 transfection reduces the SNP movement 
induction by 60.33%.  The transfection procedure alone has an 
effect as both controls also diminished induction; however, 
siMMP-1 is significantly less than either of them.  *, p<0.001 
compared to Normal; +, p<0.05 compared to either control. 
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and normal brain.  Similar observations in human melanoma cells 
and cervical and dermal fibroblasts have been reported (Yoshida 
et al., 2001; Ishii et al., 2002; Choe et al., 2003).   
 Here it is revealed that treatment of glioma cultures with 
NO donors reproducibly contributes to the in vitro invasive 
phenotype of glioma cells.  This was only observed for donor 
compound concentrations that presumably bear an amount of NO 
typical of the cNOS production range – less than one micromolar 
NO.  When reaching a donor concentration reflective of iNOS 
production – greater than micromolar range – there was a strong 
decrease in cell viability.    
 While NO clearly induced MMP-1 in glioma cells as well as 
elevating motile in vitro response it was still necessary to 
implicate MMP-1 as a potential intermediary.  Thus the 
inhibition of MMP-1 protein production was pursued through the 
transient transfection of three siRNAs (Silencer Select Pre-
Designed, Ambion) targeting exons three, five and nine of the 
MMP-1 transcript.  All siMMP-1 effectively knocked down MMP-1 
protein detection 55% to 95% at a 15nM final RNA concentration.  
Transiently transfected glioma cells subjected to the membrane 
assay showed no reduction in apparent movement without SNP 
across transfection groups.  Sodium nitroprusside educed the 
same responses as previously observed in glioma cells, but also 
enhanced the movement of siMMP-1 transfected cells versus 
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control.  However, upon examining the differences between each 
group +/- SNP, it was revealed that the NO-related induction was 
severely impaired in the siMMP-1 group.  While this was also 
seen among transfection controls, the siMMP-1 cells were still 
significantly less stimulated to translocate through the 
membrane.  Though the stress of transfection alone has an 
impact, these data lead us to conclude that MMP-1 is likely part 
of the NO-stimulated motile response. 
 Aside from their roles as extracellular matrix clearers, 
MMPs have a multitude of non-traditional substrates.  Among 
these with regard to MMP-1 is the ability to cleave Perlecan, 
IGFBP-2/3, and MMP-1/2 to release FGF, IGF and active MMP-1/2 
respectively (McCawley and Matrisian, 2001).  Furthermore, 
recent evidence points to MMP-1 as assisting in resistance to 
lamin A degradation during apoptosis (Limb et al., 2005).  
Therefore, it was necessary to test the viability of these cells 
in the presence of NO-stimulated MMP-1.  Our ATP-based assays 
showed no major differences in cell viability with the 
constitutive-like NO donor concentrations.  One millimolar NO 
donor conferred swift death within 24 hours of beginning the 
assays.  This suggests that toxicity conferred by micromolar NO 
contributes to the lack of movement at those doses.  There were 
no changes in viability observed within two days of exposure to 
L-NAME regardless of concentration. 
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 Taken together, the data presented in this study define 
aspects of NO and MMP-1 as intriguing players in high-grade 
malignant gliomas.  This underscores the importance of MMPs in 
central nervous system neoplasia.  In a recent report, Hodgson 
and colleagues (2009) show an amplification of gene 
transcription for MMP-1 and MMP-13, another collagenase, in a 
subset of GBM clinical samples.  Additionally MMP-2 can be an 
important responder to NO exposure of U-87MG cells (Lin et al., 
2008).  The same study by Lin and coworkers also presents the 
inhibition of invasion through treatment of dexamethasone, a 
known inhibitor of iNOS, thereby providing some evidence that 
iNOS may indeed have a larger role in high-grade glioma 
invasion.  
It is imperative to examine these characteristics because 
of the dichotomous roles of NO pathophysiology.  The effects of 
NO on cancer cells have emerged as especially setting/tissue 
dependent (Fukumura et al., 2006; Ridnour et al., 2006).  
Indeed, recently it has been demonstrated that a concentration 
of SNP used in this study (100µM) inhibited invasion of human 
prostate and bladder carcinoma cells (Wang et al., 2007).  The 
effects seen there were shown to have mitochondrial dependence, 
bearing importance upon the examination of cancer cell viability 
as a corollary to movement and invasion.  Interestingly it was 
also reported that HIF-1α was an effecter of hypoxia-mediated 
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invasion, yet it was ablated by the presence of NO.  However, 
tumor associated hypoxia is a key feature of high-grade glioma 
progression and in some species it is known that HIF-1α activates 
the transcription of iNOS.  Nitric oxide production is 
furthermore intertwined with VEGF over-expression common to 
high-grade astrocytomas and is a known associate of endothelial 
cell proliferation (Kaur et al., 2005).  These discordant 
concepts shed light on the importance of understanding the 
differences NO can confer on distinct cancer cell types. 
Finally, previous investigations by Gu and colleagues 
(2001) have shown the permanent activation of the latent pro-
MMP-9 via S-nitrosylation.  This form of post-translational 
modification, which targets susceptible cysteine thiols, can 
also inhibit enzyme activity, for instance the inhibition of 
certain caspases (Fukumura et al., 2006).  However, MMPs are 
manufactured in a latent pro-form, which is dependent on the 
disposition of the pro-domain from a coordinate thiol for enzyme 
activity – the cysteine switch.  Unfortunately the reliable 
detection of S-nitrosothiols is still unachievable.  Our 
attempts using the method of Jaffrey and Snyder (2001) have 
proven fruitless with regard to MMP-1.  Regardless, while this 
avenue might provide unique insights into MMP-1 activation, the 
concentration of NO required to do so is likely cytotoxic and 
beyond that which GBM cells would produce. 
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Nitric oxide synthase inhibitor use is a promising 
prospect, as seen with a reduction in glioma cell motility in 
this work.  However unlike MMP-1, cNOS isoforms are not locally 
unique to GBM.  The systemic use of NOS inhibitors is known to 
cause hypertension by inhibiting endothelial cell dependent 
vasorelaxation.  The development of specific NOS inhibitors and 
targeting techniques will be a prudent matter in the pursuit of 
this possible therapy.  As such the subsequent portion of this 
work (Chapter 3) focuses on the direct effects of MMP-1 
modulation on GBM cell tumorigenicity, and another hallmark 
pathology: tumor-induced angiogenesis. 
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III.1  Abstract  
Matrix metalloproteinase-1 (MMP-1) is a zinc dependent 
endopeptidase over-expressed in human glioblastoma multiforme 
(GBM) and has been shown to influence glioma cell migration.  
Herein the study of this enzyme with respect to GBM cell 
tumorigenicity and tumor related angiogenesis is continued.  
Glioblastoma cell lines were stably altered to either over-
express or knock down MMP-1 protein production.  Subcutaneous 
inoculation of athymic nude mice with these cells revealed that 
the presence of MMP-1 significantly increased tumor incidence 
and size.  Three-dimensional human umbilical vein endothelial 
cells (HUVECs) co-cultured with glioblastoma cells were used to 
model angiogenesis in vitro.  Endothelial projection formation 
and organized growth were significantly increased with both MMP-
1 expression and exogenous application of recombinant protein.  
Immunohistochemical analysis of tumors for CD31, specific for 
endothelial cells, elucidated a substantial recruitment of 
endothelium in MMP-1 expressing tumors.  Further in vitro 
angiogenesis analysis with targeted antibody arrays indicated an 
inverse expression of certain anti-angiogenic factors with 
respect to MMP-1 expression.  The most notable of these changes 
was a significant increase in tissue inhibitor of 
metalloproteinases (TIMP) -4 expression in the absence of MMP-1, 
as validated by immunoblot.  Angiogenesis assays using TIMP-4 
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confirm its anti-angiogenic properties.  Taken together these 
data indicate that MMP-1 contributes to GBM cell tumorigenicity, 
possibly via the regulation of anti-angiogenic molecules.  In 
addition to its pro-invasive property, this pathologically local 
enzyme is also pro-angiogenic.  We propose that these key 
features highlight MMP-1 as a promising target for in depth pre-
clinical study and targeting in GBM. 
III.2  Introduction  
The most aggressive type of malignant primary brain tumor, 
glioblastoma multiforme (GBM), is also the most common, 
accounting for about half of all malignant gliomas.  Even with 
current standard therapies – surgical de-bulking, irradiation, 
temozolomide – patient survival beyond two years post-diagnosis 
remains low and symptoms grim (Louis et al., 2002; Buckner et 
al., 2007; Fisher et al., 2007).  While the paradigm of 
temozolomide treatment concomitant with radiotherapy and six 
months adjuvant thereafter has resulted in definitive extension 
of survival time (Stupp et al., 2005; Jeon et al., 2009), more 
recent strides are being taken in advancing treatment based upon 
targeting specific angiogenic pathways and related signaling 
cascades (Gillespie et al., 2007; Mathieu et al., 2008; Gu et 
al., 2009; Kärrlander et al., 2009).  Indeed, profuse 
endothelial hyperplasia and invasion are defining 
characteristics of GBM.  Intrinsic to these pathological 
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features are extracellular matrix (ECM) cues and activities.  In 
particular, the expression of matrix metalloproteinases (MMPs) 
is vital to the mediation of ECM composition, tumor cell 
navigation, and the release of bioactive molecules that can be 
pro-tumor (McCawley and Matrisian, 2001).   
It has been previously demonstrated that the expression of 
MMP-1, also known as interstitial collagenase, is an important 
characteristic of GBM.  Not normally found in the developed CNS, 
MMP-1 is profoundly over-expressed in GBM patient samples at the 
mRNA and mature protein levels (McCready et al., 2005; Stojic et 
al., 2008; Hodgson et al., 2009).  Recently it has been shown 
that MMP-1 can induce angiogenesis (Blackburn and Brinckerhoff, 
2008).  Furthermore, this enzyme has been found to enhance 
motility and invasion in GBM cells and other cancer settings 
(Benbow et al., 1999; Yoon et al., 2003; Blackburn et al., 2007; 
Blackburn et al., 2009).  The control of MMP-1 expression is 
multifaceted, for instance it is theorized that promoter 
activation can result from the prevalence of a single nucleotide 
polymorphism that introduces an element responsive to the MAPK 
cascades (Rutter et al., 1998; McCready et al., 2005).  Nitric 
oxide induces the expression of MMP-1 and glioma cell motility 
(Pullen and Fillmore, 2010 [Chapter 2]), and can post-
translationally activate at least one other MMP (MMP-9) via S-
nitrosylation (Gu et al., 2002; Harris et al., 2008).  
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Additionally, all MMPs can be controlled by their endogenous 
inhibitors: the tissue inhibitors of metalloproteinases (TIMPs), 
a family of four proteins that bind MMP active sites, thereby 
preventing proteolytic cleavage of substrates.  Contrary to its 
namesake, TIMP-2 has been shown to interact with MT-1 MMP to 
facilitate the activation of MMP-2 (Hernandez-Barrantes et al., 
2000; Wang et al., 2000), which is an indicator of poor 
prognoses in multiple cancers (Björklund and Koivunen, 2005).  
Comparably less is known about the TIMPs and their potential 
functions in GBM.  It has been reported that differential 
expression levels of TIMP-1 and TIMP-4 within high-grade 
malignant gliomas might correlate with longer survival (Groft et 
al., 2001; Aaberg-Jessen et al., 2009).  Furthermore, TIMPs are 
regarded as inhibitors of angiogenic processes (Brew et al., 
2000; Rege et al., 2005).   
Despite these observations, there have been few functional 
analyses into the importance of MMP-1 in GBM.  While the 
examination of MMPs might have been abandoned by many due to the 
unacceptable side effects of an inhibitor in clinical trial in 
the past decade (Groves et al., 2002), we submit that the 
continued investigation of these enzymes will contribute to the 
collective understanding of GBM. 
The experiments described herein were performed with a 
focus on the functional impacts of MMP-1 expression in GBM 
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cells.  Expression of MMP-1 not only enhanced the formation of 
tumors, but also their sizes.  Glioma cells and recombinant MMP-
1 clearly induced endothelial cell morphology indicative of 
angiogenesis in an in vitro model (Chen et al., 2009), in a MMP-
1 dependent manner.  Subsequent immunohistochemical examination 
of model tumor specimens elucidated a striking recruitment of 
endothelium throughout MMP-1 over-expressing tumors.  
Interestingly, proteomic analyses using antibody arrays against 
angiogenesis related factors revealed anti-angiogenic expression 
patterns inverse to the levels of MMP-1.  By far the greatest of 
these changes was in the detection of TIMP-4, which 
significantly increased with the removal of MMP-1.  The anti-
angiogenic role of TIMP-4 was confirmed with the in vitro 
angiogenesis model.  These data serve as evidence in support of 
MMP-1 and related factors as potential, focused targets to GBM 
angiogenesis and invasion, and warrant continued investigation 
into their actions and controls in the context of GBM biology.  
 
III.3  Materials & Methods 
 
Cell Culture 
U251 MG and T98G cell lines were obtained from American Type 
Culture Collection (ATCC, Manassas, VA) and cultured as 
previously described (Pullen and Fillmore, 2010 [Chapter 2]).  
Human umbilical vein endothelial cells (HUVEC) and their growth 
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medium (EGM-2) were obtained from Cambrex Bio Science 
(Walkersville, MD) and grown as in Chen et al., 2009. 
Over-expression and knock-down of MMP-1 protein 
U251 MG cells were stably transfected with the pIRES-GFP-MMP-1 
vector containing sequences for green fluorescent protein and 
MMP-1, as well as G418 resistance.  Two million cells were 
transfected with 1µg DNA using the Oligofectamine™ transfection 
method according to the manufacturer’s protocol (Invitrogen, 
Carlsbad, CA).  Three days after transfection, medium containing 
500µg/ml G418 (Invitrogen) was added to the U251 MG-vector 
control and MMP-1 over-expressing transfectants.  The G418–
resistant cells were selected and grown for further experiments. 
Afterwards, these cells were stably maintained in complete DMEM 
supplemented with 400µg/ml G418. 
T98G cells were stably transduced with MISSION™ lentiviral 
shMMP-1 particles (Sigma-Aldrich, St. Louis, MO) to knock down 
production of the protein.   Transduction was carried out 
according to the manufacturer’s protocol using a multiplicity of 
infection equal to fifteen.  Stable colonies were selected over 
a period of one month under pressure of 1µg/mL puromycin (Sigma-
Aldrich) supplemented complete DMEM.  After confirmatory 
immunoblots of MMP-1 knock-down (>50% by semi-quantitative 
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densitometry), stable clones were maintained under the same 
puromycin selection pressure. 
Immunoblot 
Cell culture proteins were isolated with RIPA buffer as 
described previously (Pullen and Fillmore, 2010 [Chapter 2]).  
Tumor lysates were obtained by first grinding liquid nitrogen 
snap-frozen specimens to a fine powder, and then by applying 
tissue protein extraction reagent (T-PER, Thermo Scientific, 
Rockford, IL) according to the manufacturer’s protocol.  Total 
protein concentration was determined using the DC Protein Assay 
(Bio-Rad, Hercules, CA).  
Samples were resolved by SDS-PAGE as in Pullen and 
Fillmore, 2010 (Chapter 2).  Primary antibodies and respective 
dilutions were: 2µg/mL mouse α-human MMP-1 (MAB 901, R & D 
Systems, Minneapolis, MN), 2µg/mL mouse α-human TIMP-4 (MAB974, 
R & D Systems), or 1:5000 rabbit α-human Cyclophilin A (07-313, 
Millipore, Billerica, MA).  A dilution of 1:3000 HRP-conjugated 
secondary antibodies (Rockland Immunochemicals, Gilbertsville, 
PA) was utilized; either goat α-mouse (610-1302) or α-rabbit 
(611-1302) IgG.  Immunoreactivity was detected with Enhanced 
Chemiliuminescence Reagents (ECL, GE Healthcare, 
Buckinghamshire, UK) followed by exposure to and development of 
autoradiographic film (Genesee Scientific, San Diego, CA).  
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Films were digitally scanned and densitometric analyses were 
performed using ImageJ (NIH, Bethesda, MD). 
In vivo Tumor Growth 
The growth of U251 MG and T98G cells was assessed in athymic 
nude mice (Hsd: Athymic Nude-Foxn1nu, Harlan Sprague-Dawley, 
Indianapolis, IN) using a subcutaneous flank inoculation model.  
Cells were rinsed three times with 1X DPBS (Invitrogen) then 
suspended at 2.5 x 106 cells/mL (U251 MG) or 5x106cells/mL (T98G) 
in a 1:1 plain DMEM (no supplements) to growth factor reduced 
Matrigel™ (BD, Franklin Lakes, NJ) solution.  Mice were 
inoculated subcutaneously in their hind flanks with 200µL of this 
suspension in three separate cohorts per cell type (U251 MG 
controls, U251 MG over-expresser, T98G controls, T98G knock-
down); to attain eight to ten overall inoculates per cell type.  
Tumor take was assessed by the formation of a palpable mass 
within seven days post-inoculation, and growth was assessed over 
three weeks using external caliper measurements according to the 
formula: (LxW2)÷2, where L=longest axis and W=shortest axis.  
Representative tumors were excised and either fixed in 10% 
formalin for downstream histological analyses, or snap-frozen in 
liquid nitrogen and stored -80oC for subsequent immunoblots.  The 
VCU Institutional Animal Care and Use Committee approved these 
experiments in accordance with federal and local guidelines 
under protocol number AD20136. 
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In vitro Angiogenesis Model Assay 
Our laboratories have developed an in vitro model of glioma-
induced angiogenesis, the method of which is explicitly detailed 
in Chen et al., 2009.  The principals of the assay involve first 
coating Cytodex™ 3 microcarrier beads (Amersham-GE Healthcare) 
with HUVECs, then immobilizing the coated beads in a three-
dimensional fibrin gel environment.  The gels were overlaid with 
complete EGM-2, which can include desired soluble factors of 
study, or other cells for co-culture.  Previously, it has been 
demonstrated that HUVEC sprout formation and growth from the 
beads can be induced with VEGF or glioma cell co-cultures.  
Without angiogenic cues the HUVECs randomly migrate away from 
the beads over time.  This assay was performed for this work 
with co-culture of the aforementioned stably altered glioma 
cells.  Furthermore, beads were also cultured in the presence of 
10ng/L recombinant human (rh)MMP-1 (901-MP-010, R & D Systems), 
and 50ng/L rhTIMP-4 (974-TSF-010, R&D Systems).  After five 
days, with refreshment of media at the end of day two, the 
number of sprouts per bead was counted and lengths measured 
using SPOT Advanced v3.2.4 software and camera (Diagnostic 
Instruments, Inc.) calibrated to the objective magnification 
settings of an Olympus CK40 microscope. 
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Histologic and Immunohistochemical Processing 
Representative in vivo tumors were taken and post-fixed in 10% 
formalin.  Specimens were paraffin embedded and 6µm thick serial 
sections used for H&E staining and CD31 (PECAM-1) 
immunohistochemistry.  Antigen retrieval was conducted by 
heating sections to 100oC for 20 minutes.  Rat anti-mouse CD31 
primary antibody (550274, BD Pharmingen) was applied to the 
samples in a 1:50 dilution in horse serum, followed by 
incubation with a biotinylated rabbit α-rat secondary (BA-4001, 
Vector Laboratories, Burlingame, CA), and development by the DAB 
method with the VECTASTAIN® Elite ABC kit according to the 
manufacturer’s protocol (Vector Laboratories).  Sections were 
counterstained with hematoxylin.   
Positivity for CD31 was determined using an automated 
Ariol® slide quantification platform (Genetix Corp., San Jose, 
CA).  Briefly, the computer operated Olympus BX61 microscope 
loaded individual slides and scanned tissue sections at 20X 
objective magnification.  Once all scanning was completed, 
quantification of CD31 positivity was calculated based upon 
multiple color channels as well as the morphology of 
immunoreactivity.  These values were reported in square microns, 
and then transformed to a percentage of total area analyzed per 
region of interest. 
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Proteomic Profiler Antibody Arrays 
Human angiogenesis antibody arrays (ARY007 R&D Systems) were 
utilized according to the manufacturer’s protocol.  These arrays 
consisted of nitrocellulose membranes spotted in duplicate with 
antibodies raised against 55 angiogenesis related proteins 
(Table 3.1).  Briefly, RIPA lysates from multiple passages of 
the glioma cell lines within each condition were pooled.  Each 
condition, e.g. T98G control or T98G MMP-1 knock-down, was 
incubated with a biotinylated detection antibody, while 
membranes were blocked, at ambient temperature prior to 
overnight incubation at 4oC with individual membranes per pooled 
condition. Membranes were washed and incubated with 
streptavidin-HRP, followed by another wash and immersion in ECL 
Reagents.  Immunoreactivity was detected by membrane exposure to 
autoradiographic film.  Developed films were densitometrically 
analyzed in the same fashion as immunoblots. 
Statistics 
JMPv8 software (Cary, NC) was utilized for the statistical 
analyses of data.  Student’s t-test was performed for 
comparisons among groups in experiments reported with continuous 
data.  For categorical tumor take data, Fisher’s Exact Test was 
calculated.  Differences were deemed significant for p<0.05. 
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Table 3.1.  Angiogenesis proteome profiler.  Antibodies directed 
against the following angiogenesis related proteins were 
utilized in the proteomic profiler arrays. 
 
 
 
 
  105 
 
 
 
 
!"#$%&'!' ()(*+,-)(' ./*01)('
!/!234*5' )/6(' ./)(*!!'
!&7%879&%&' )2*14(' ./)(*!:,./)(*::'
!&7%8;8%9#&*5' <:*0)(' .9=>9;?%&'
!&7%8;8%9#&*@' <)(' 1A1BC,.(C'
!&7%8>DE#&,.FE>G%&879&' H)(:.*5' .F)('
!G;?%=97IF%&' H)(:.*@' .=8FE"#&'
!=D9G%&' H)(:.*J' 49=;%&':K,2E>;%&'
3%>>I9'(E"D8=,(E"D8='HHH' HB*5'L9DE' 49=;%&'05,.!H*5'
1A1B5M' 1A1BN,HB*N' 49=;%&'(5,.0/('
/..HO,1/@M' B!.'P3)(*L9DE'5Q' 3H2.*5'
0)(' B9;#&' 3H2.*C'
0)*O0)(' 11B@,21.*5' 3?=8GL8>;8&R%&*5'
0&R87F%&,1/5SK' 11BJ,2H.*5'EF;?E' 3?=8GL8>;8&R%&*@'
0&R8>DE#&,18FFE79&'AOHHH' 22.*N' I.!'
0&R8D?9F%&*5' 22.*T' OE>8?%L%&'
()('E"%R%"' 6U)5*L9DE'5' O0)('
()('LE>%"' .9&D=EV%&'J' O0)(*1'
()(*C'
  106 
III.4  Results 
 
Stable manipulation of MMP-1 expression and glioma cell 
tumorigenicity  
Previously our laboratories reported the over-expression of MMP-
1 in GBM patient samples (McCready et al., 2005) as well as 
glioma cell dependence on MMP-1 expression for NO-induced 
motility (Pullen and Fillmore, 2010 [Chapter 2]).  Matrix 
metalloproteinases are not simply regarded as ECM clearance 
enzymes, but are also potent liberators of bioactive, pro-tumor 
factors.  Prior experiments examined the control of MMP-1 
expression in a transient, in vitro context, thus the next 
evolution of this work was to establish stable over-expression 
and knock-down of MMP-1 protein in different glioblastoma cell 
lines, and then to assess the impact of MMP-1 on glioblastoma 
cell tumorigenicity in vivo. 
U251 MG cells do not produce an appreciable level of MMP-1 
under standard culture conditions.  Therefore this cell line was 
chosen for the stable over-expression of MMP-1.  This was 
successfully accomplished using a pIRES-GFP vector with stable 
maintenance under the selection pressure of G418 (Figure 3.1A).  
Conversely, T98G cells produce MMP-1 under standard conditions.  
These cells were transduced with various lentiviral clones 
containing MMP-1 shRNA sequences and puromycin resistance.  
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Clone 36 (TRCN0000003336, NM_002421.x-1702s1c1) proffered 
complete knock-down of MMP-1 protein as assessed by immunoblot 
(Figure 3.1B). 
These MMP-1 manipulated cells were then examined in vivo.  
Subcutaneous flank inoculation of athymic nude mice was chosen, 
because it models a non-permissive growth environment in which 
tumor cells must appropriately sense and respond to their 
surroundings to maintain viability, and provides an efficient 
mode of direct tumor growth observation.  The first grossly 
observable effect of changes in MMP-1 expression was an impact 
on the ability of glioma cell inoculates to form tumors.  All 
T98G control inoculates produced palpable tumors; however, fewer 
than 40% of those with stable MMP-1 knock-down formed (p<0.05, 
Table 3.2).  Similarly, with regard to MMP-1 expression, U251 MG 
control inoculates had approximately 50% tumor take, whereas 
100% of MMP-1 over-expresser inoculates developed tumors 
(p<0.05).  Furthermore, the tumors that did form in the T98G 
MMP-1 knock-downs and U251 MG controls had significantly reduced 
volumes compared to their respective MMP-1 expressing 
counterparts (p<0.05, Figure 3.2A&B).  Eventually all T98G MMP-1 
knock-down tumors regressed.  To determine if MMP-1 expression 
was maintained, representative tumors were excised, snap frozen, 
and proteins isolated for MMP-1 immunoblot. Greater than 50% 
MMP-1 knock-down was observable in T98G tumor lysates, while 
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Figure 3.1.  MMP-1 immunoblots of stable MMP-1 manipulation 
(cyclophilin A used as a loading control) demonstrating A, U251 
MG cells that were stably transfected with a pIRES-GFP-MMP-1 
G418 resistant cDNA vector to over-express MMP-1 protein.  B, 
T98G cells that were stably transduced with lentiviral particles 
coding for shMMP-1 and puromycin resistance for MMP-1 protein 
knock-down. P:parental; VC:Vector Control; MMP-1+:MMP-1 over-
expresser; NT: non-target shRNA lentivirus; sh: MMP-1 knock-down 
lentivirus. 
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Table 3.2.  Categorical palpable tumor formation within seven 
days post-inoculation. Ŧp<0.05 
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Tumor Type Tumor Take 
by 1 week(%) 
U251 Control 55.6 (n=9) 
U251 + MMP-1! 100 (n=9) 
T98G Control 100 (n=10) 
T98G shMMP-1! 37.5 (n=8) 
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there was greater than twice the level of immunodetection in 
U251 MG MMP-1 over-expressers compared to relevant controls 
(Figure 3.2C&D).  It should be noted that MMP-1 production can 
be induced in U251 MG control cells in an in vivo context.  
These data suggest that MMP-1 expression is vital for glioma 
cell tumorigenicity. 
Influence of MMP-1 expression in an in vitro model of 
angiogenesis 
One of the defining characteristics of GBM is extensive tumor-
associated endothelial hyperplasia.  Advances in targeting 
factors associated with angiogenic cascades in GBM have begun to 
display clinically meaningful treatments for this disease.  
Recently, it has been proposed that MMP-1 could also fulfill a 
pro-angiogenic role in cancer (Blackburn et al., 2007 & 2009).  
Therefore we pursued the examination of glioma cell associated 
angiogenic induction with respect to MMP-1 expression in an in 
vitro model established in our laboratories (Chen et al., 2009).  
Cytodex™3 microcarrier beads were coated with HUVECs then 
immobilized in a three-dimensional cell culture environment.  
HUVECs randomly migrate and fall away from the microcarrier 
beads when only basic growth medium is placed over the gels.  
With the co-culture of MMP-1 expressing glioma cells there was 
an induction of HUVEC projection formation and growth from the 
coated beads.  Specifically, over-expression of MMP-1 in U251 MG 
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Figure 3.2.   In vivo experiments on the tumorigenicity of 
glioblastoma cells with altered MMP-1 expression.  A, growth of 
T98G inoculates over three weeks.  B, growth of U251 MG 
inoculates over three weeks.  Growth is presented as mean volume 
(mm3) by external caliper measurement according to the modified 
ellipsoid formula (LxW2)÷2; n=8-10 per condition, divided among 
three separate cohorts *p<0.05.  C (T98G) and D (U251 MG) are 
MMP-1 immunoblots on representative tumor lysates twelve days 
post-inoculation, demonstrating the continued, stable alteration 
of MMP-1 expression in vivo. 
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induced greater sprout length versus controls (p<0.05, Figure 
3.3A) and knock down of MMP-1 expression in T98G reduced length 
(p<0.05, Figure 3.3B).  When rhMMP-1 was included with the 
growth medium, without glioma cell co-culture, there was an 
increase in HUVEC projection number and length (p<0.05 Figure 
3.3C&D), indicating that in vitro MMP-1 is a glioma cell 
related, pro-angiogenic component. 
In vivo assessment of glioma related MMP-1 pro-angiogenic 
potential 
Based upon the in vitro model results we hypothesized that MMP-1 
expression would contribute to an angiogenic response from 
glioblastoma cells in vivo.  Representative tumors from the 
initial tumorigenicity experiments were excised and post fixed 
in 10% formalin for the purpose of histological examination.  
T98G MMP-1 knock-down did not produce appreciable tumor 
quantities, both in number and size, for multiple reliable 
analyses.  Hematoxylin & eosin simple stained paraffin embedded 
sections suggested qualitatively that there were more vascular 
structures present in U251 MG MMP-1 over-expressing tumors 
(Figure3.4A&B), especially in peripheral tumor associated 
stroma.  Thus U251 MG control and MMP-1 over-expressing tumors 
were subjected to immunohistochemistry for a more definitive 
observation of tumor-associated endothelium and potential 
quantification. 
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Figure 3.3.  In vitro angiogenesis assays in the context of MMP-
1 expression.  A (U251 MG) and B (T98G) present endothelial cell 
projection length from endothelial coated Cytodex™ beads co-
cultured in a three-dimensional environment with glioblastoma 
cells.  C, average number of projections per bead in the 
presence or absence of rhMMP-1 (10ng/L) and D, length of those 
projections, there was no co-culture involved in C&D.  *p<0.05. 
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Also known as platelet endothelial cell adhesion molecule-1 
(PECAM-1), CD31 is acknowledged as a marker of endothelium, the 
immunoreactivity of which is often utilized for the analysis of 
microvascular density in pathological specimens.  A monoclonal 
antibody raised against mouse CD31 was used to detect the 
endogenous recruitment of vessels in vivo.  Immunoreactivity was 
specific for vascular endothelium and not other ductile tissue 
within the sections.  Furthermore, there was a profound increase 
in CD31 immunoreactivity within MMP-1 over-expressing tumors 
compared to U251 controls (Figure 3.4C&D).  Vast, anastamosing 
networks of positivity were observed in MMP-1 over-expressers 
that were not seen in low MMP-1 expressers.  Indeed, these 
networks were so profuse that quantification of discrete blood 
vessels became difficult.  Therefore the use of an automated 
Ariol® slide quantification platform was pursued.  The 
instrument software was trained to recognize true positive 
immunoreactivity through the utilization of multiple color 
channels, and importantly through the morphology of 
immunoreactivity.  After scanning and analyzing 
immunohistochemical sections including negative (no primary 
antibody) controls, it was determined that on average 3.26% of 
any given region of interest in a U251 MG control tumor was 
CD31/vessel-shape positive.  The MMP-1 over-expressing tumors  
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Figure 3.4.  Analysis of endogenous vascular recruitment in MMP-
1 over-expressing tumors.  A (U251 MG control) and B (U251 MG 
MMP-1 over-expresser) are representative H&E sections.  C (U251 
MG control) and D (U251 MG MMP-1 over-expresser) are CD31 DAB 
immunohistochemical sections counter-stained with hematoxylin; 
red asterisk in D indicates a non-endothelial, ductile structure 
that is not immunoreactive for CD31.  E, automated Ariol 
platform analysis of CD31 immunohistochemistry, where positivity 
is represented by percent of total region of interest area based 
upon multiple color channels and the morphology of 
immunoreactive structures (n = 3 tumors per condition, total of 
9). *p<0.05. 
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were 22.29% positive (p<0.05, Figure 3.4E).  These observations 
indicate that tumor produced MMP-1 was contributing to a 
significant recruitment of host nascent vascular structures 
within tumors in vivo. 
 
Angiogenic protein profile in glioma cells with respect to MMP-1 
expression 
While MMP-1 clearly induced angiogenesis in vivo, and with in 
vitro modeling, the route(s) taken to do so remain unknown.  For 
future studies it was sought to identify angiogenesis related 
proteomic changes that might occur in the context of shifts in 
MMP-1 expression.  Glioma cell lysates from multiple passage 
points were pooled and applied to arrays spotted with 55 
antibodies raised against factors known to be involved in 
angiogenesis.  An inverse relationship between MMP-1 expression 
and the detection of certain anti-angiogenic proteins, such as 
endostatin and platelet factor 4 (CXCL4) was observed.  However, 
most notable in these shifts was a substantial increase in the 
detection of TIMP-4 (Figure 3.5A&B) in the absence of MMP-1.  
There were no remarkable shifts in the detection of pro-
angiogenic proteins with changes in MMP-1.  This does not 
preclude the possibility that MMP-1 could induce other pro-  
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Figure 3.5.  TIMP-4 expression with MMP-1 knock-down.  A (T98G 
control) and B (T98G MMP-1 knock-down) present representative 
angiogenesis-related proteomic antibody arrays; circles denote 
the TIMP-4 duplicate antibody spots.  C, representative MMP-1 
and TIMP-4 immunoblot on T98G lysates to confirm by a resolved 
protein assay that with the knock-down of MMP-1 there is an 
increase in TIMP-4 immunodetection.  D, densitometry on TIMP-4 
immunoblots tested on different lysates (n =4 per condition).  
*p<0.05. 
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angiogenic mediators, e.g. protease activated receptor-1 (PAR-
1), which were not included in these arrays. 
Confirmation of MMP-1 dependent TIMP-4 protein expression and 
anti-angiogenic role 
One of the sacrifices of high-throughput antibody arrays is an 
increased chance for off-target antigen detection, since the 
protein lysates are not resolved.  It is well known that TIMPs 
can complex to other proteins with marked promiscuity.  
Therefore, traditional immunoblot analyses were performed to 
confirm changes in TIMP-4 protein levels.  Glioma cell lysates 
were individually examined across multiple passage points, and a 
consistent increase in TIMP-4 detection in the absence of MMP-1 
was observed (p<0.05, Figure 3.5C&D). 
Recently, TIMP-4 has been reported to be a potent inhibitor of 
microvessel growth in an ex vivo aortic ring model of 
angiogenesis (Aplin et al., 2009).  Thus, the confirmation of 
these observations was sought with the microcarrier bead in 
vitro model.  Both endothelial cell projection length and number 
were significantly reduced in the presence of rhTIMP-4 (p<0.05, 
Figure 3.6A&B).  The combination of rhMMP-1 and rhTIMP-4 impeded 
projection length more so than TIMP-4 alone, while not 
significantly altering the number of projections per bead.  Thus 
the anti-angiogenic properties of TIMP-4 were confirmed with the  
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Figure 3.6.  In vitro angiogenesis assays in the presence of 
rhMMP-1 (10ng/L), rhTIMP-4 (50ng/L), and in combination.  A, 
endothelial cell projection length.  B, endothelial cell 
projection number.  *p<0.05.  
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in vitro model, and its inverse relationship with MMP-1 
expression, a traditional TIMP target, indicate a need for 
continued investigation. 
III.5  Discussion 
 
Glioblastoma is particularly insidious because of its ability to 
aggressively infiltrate the normal host parenchyma.  Invariably 
this tumor cell diffusivity contributes to recurrence after 
treatment of the primary tumor.  Therefore it is within reason 
to pursue the inhibition of pro-invasive factors such as the 
MMPs.  It is known that MMP-1 is expressed in human GBM while 
not in normal brain, and that the knock-down of MMP-1 impairs 
GBM cell motility.  However, it is also important to consider 
that MMPs are capable of much more than the clearance of ECM in 
a physical barrier context.  Among the non-traditional 
substrates for MMP-1 are perlecan, insulin growth factor binding 
proteins, the pro-gelatinases (MMPs-2 and -9), and PAR-1 
(Blackburn and Brinckerhoff, 2008).  This implies a potential 
tumorigenic role for MMP-1 not just through the direct 
facilitation of invasion, but also via the activity enhancements 
of other pro-invasive enzymes and the release of mitogenic 
growth factor cues.  Within this work it is reported that the 
expression of MMP-1 significantly influenced tumor incidence in  
in vivo.  Increased levels of MMP-1 were consistent with 
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enhanced tumor take, as well as the size of tumors for all times 
examined.  
More recently, the inhibition of VEGF has led to promising 
survival extension in recurrent GBM and is under trial with new 
diagnoses.  However, detailed mechanisms are not entirely 
understood, and notable concerns have arisen regarding the 
physiology behind tumor responses (Verhoeff et al., 2009).  The 
investigation of other tumor angiogenesis targets is needed and 
currently underway.  Blackburn, Brinckerhoff, and colleagues 
(2007, 2008 & 2009) have reported compelling evidence that MMP-1 
is a pro-angiogenic mediator in a melanoma setting through the 
activation of PAR-1 in a site unique from that of thrombin.  
Knowing that profuse tumor-associated angiogenesis is a hallmark 
of GBM pathology and with the knowledge that GBMs manufacture 
MMP-1 in an environment free of this protease, a similar effect 
was hypothesized.  Three-dimensionally stabilized HUVECs were 
induced to proliferate and differentiate into sprouting, cord-
like structures when co-cultured with GBM cells, while otherwise 
randomly migrating in an undifferentiated state; thus 
establishing a GBM cell induced in vitro angiogenesis model.  
Herein it was observed that the presence of MMP-1 significantly 
enhanced sprout extension in HUVEC-GBM cell co-cultures.  When 
cultured without the GBM cells, but recombinant human MMP-1 
alone, HUVECs were still induced to form sprouts.  These data 
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complement others in the literature previously mentioned and 
confirm that MMP-1, at least in an in vitro setting, is involved 
in GBM cell induced angiogenesis.    
The in vitro model relies on controlled and spatially 
distinct co-cultures thus this MMP-1 mediated angiogenic 
potential was assessed in vivo using U251 MG flank tumors via 
CD31 immunohistochemistry.  There was an intense induction of 
CD31 immunoreactivity with MMP-1 over-expressing tumors versus 
controls.  Endothelial structures were not just prevalent 
surrounding the tumor mass but invested the entire tumor 
interstitium more heavily than low expressing MMP-1 controls.  
Nearly 7-fold higher CD31 positivity was observed with MMP-1 
expression, lending more evidence to the multi-faceted 
pathological roles that MMP-1 might fulfill in GBM.  The 
contrast with respect to the scale of MMP-1 dependent changes 
between the in vitro and in vivo settings highlights the complex 
balance of angiogenic signaling events involved and gaps between 
in vitro vs. in vivo systems.  We posit that MMP-1 is a major 
tumor produced factor contributing to the angiogenic switch 
characteristic of GBM (Tate and Aghi, 2009).   
In light of our hypothesis and the aforementioned results, 
55 angiogenesis related proteins were examined using 
commercially available antibody arrays.  Strikingly, no 
substantial changes in pro-angiogenic factors were observed in 
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the context of MMP-1.  We submit this as an additional emphasis 
of the complex balance between anti- and pro-angiogenic factors.  
Indeed, upon assessment of anti-angiogenic factors, several were 
found to have inverse detection with respect to the level of 
MMP-1 protein.  The most remarkable of these changes was with 
TIMP-4, with its detection significantly higher in GBM cell 
lysates without MMP-1 expression.  Therefore it is proposed that 
MMP-1 could be serving tumors by easing anti-angiogenic 
pressures. 
It is widely accepted that all TIMPs are anti-angiogenic 
through the inhibition of MMPs that contribute to endothelial 
migration, halting endothelial cell cycle progression, and 
ablation of VEGF expression (Rege et al., 2005).  However, there 
remains a dearth of literature with regard to TIMP-4, the newest 
member of that family.  The most recent study displays evidence, 
from an aortic ring model, that TIMP-4 inhibits nascent vessel 
growth from the aortic slice, while stabilizing microvessels 
that already passed through an angiogenic cycle without TIMP-4 
(Aplin et al., 2009).  An earlier set of work confirmed the 
anti-migratory effect of TIMP-4 but reported no change in vessel 
formation in a chick chorioallantoic membrane model (Fernández 
and Moses, 2006).  Thus TIMP-4 was applied to the HUVEC coated 
microcarrier bead assay and it was observed that rhTIMP-4 
inhibits both the formation and organized growth of endothelial 
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projections.  The two prior mentioned studies and this one, 
while having differences among them, all confirm at least one 
aspect of the anti-angiogenic property of TIMP-4; the points of 
contention could be attributed to the distinct methods among the 
models and the intrinsic theoretical practice of in vitro 
systems.   
Matrix metalloproteinase-1 offers outstanding potential as 
a therapeutic target by at least three standards: it is unique 
to GBM with respect to the local host parenchyma, it is pro-
angiogenic, and it is pro-migratory and invasive. Unfortunately 
in the past decade, the use of a MMP non-specific inhibitor in a 
phase II trial resulted in intolerable joint pain side effects 
(Groves et al., 2002).  Current MMP inhibitors have broad 
effects, and potential MMP substrates remain difficult to 
predict; these factors underline the need for an assemblage of 
structural biology investigation and expertise into these 
enzymes.  Furthermore, the interplay of MMP-1 with anti-
angiogenic proteins as discussed in this work could be exploited 
for clinical value and warrants extensive continued exploration.  
The inverse relationship between MMP-1 and TIMP-4 is 
particularly intriguing in light of the generally accepted 
principal that TIMPs inhibit MMPs; the discovery of the 
mechanisms underlying this relationship will be of exceptional 
scientific value.  
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IV.1 Summary of Thesis Results 
 
Herein is outlined experimentation into the important roles of 
MMP-1 in GBM biology.  The first set of experiments set out to 
examine the potential stimulation of MMP-1 protein production by 
the small bioactive diatomic free radical NO.  The rationale 
behind this can be set forth by at least three relevant points: 
first, the expression of the enzymes that produce NO, the NOS, 
is higher with increasing grade of astrocytoma, peaking in GBM; 
second, this profile overlaps with a locally unique over-
expression of MMP-1 in patient samples (Table 1.3; McCready et 
al., 2005); and third, NO is known to positively influence 
multiple signal transduction pathways that are aberrantly 
amplified in the GBM condition, of which, specifically the MAPK 
cascades, the MMP-1 promoter is exquisitely sensitive. 
 With the use of NO donors at a concentration that reflects 
the production of cNOS, significant increases in MMP-1 mRNA and 
protein were observed indicating a causal expressive link.  
However, there remained a question of function.  Application of 
the NO donors significantly enhanced glioma cell motility in 
vitro.   However, more important was the finding that with the 
transient inhibition of MMP-1 protein production with RNA 
interference technology, there was a substantial abrogation of 
the NO-induced migratory response.   
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This is a key point of study since one of the most 
difficult aspects of GBM treatment is the inability to access 
small populations of tumor cells that migrate away from the 
surgically resectable tumor mass.  Eventually these migratory 
cells, intimately interspersed throughout the host parenchyma, 
cause recurrent lesions that lead to death.  Matrix 
metalloproteinase are integral components of cellular motility 
and invasion.  It is important to note that MMP-1 is not the 
only MMP with proven pathological activity in GBM, but what 
makes it an attractive candidate is the fact that its expression 
is profoundly unique to the tumor and that it possesses the 
ability to liberate other factors and MMPs, specifically the 
gelatinases which have been well-studied with respect to GBM 
cell invasion.  Targeting the activity of NOS is promising 
because of the vast knowledge on signaling systems and plethora 
of pharmacological inhibitors that are available for pre-
clinical study.  Indeed, within this body of investigation 
(Chapter 2) it was observed that the use of one of these 
inhibitors, L-NAME, significantly reduced GBM cell migration.   
The second portion of this work focused upon the importance 
of MMP-1 in GBM with explicit attention to tumorigenic and 
angiogenic pathologies.  Glioblastoma cells are particularly 
hardy in the non-permissive host environments – by exploiting a 
poorly understood complex arrangement of cell survival, matrix 
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sensing, and degrading signals GBM cells are able to settle, 
reproduce, and spread through normal host tissue.  Furthermore, 
they secrete factors that lead to the profuse production of 
leaky and sometimes non-circulating blood vessels.  The bases of 
these pathologies are not completely understood and require 
continued investigation.  As such models of tumorigenicity and 
angiogenesis were examined in the context of MMP-1 expression. 
Two GBM cell lines were engineered to stably over-express 
or inhibit MMP-1 protein production depending upon their 
parental cell phenotypes.  These MMP-1 modified cells were then 
grown subcutaneously.  It was observed that GBM cell 
tumorigenicity was significantly dependent upon MMP-1 expression 
status, which was confirmed with MMP-1 immunodetection in tumor 
lysates.  In the presence of MMP-1, the formation of palpable 
tumors was approximately twice that in cells without the enzyme.  
Furthermore, the sizes of tumors that formed in groups with 
lower MMP-1 expression were half the volume of their respective 
counterparts.   
Viability data from the NO experiments and as yet 
unpublished work by Anand and colleagues (2010) show that MMP-1 
does not directly enhance GBM cell proliferation in vitro, nor 
does it impede survival or cellular reproduction.  These 
collective data suggest two possibilities to account for 
increased tumorigenicity that likely overlap in an in vivo 
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setting.  First, as mentioned previously, there exists a 
multitude of non-traditional MMP-1 substrates in the host 
interstitium, which upon activation or release by MMP-1 proffer 
widespread effects on not just invasion but also growth and 
resistance to apoptosis.  Second, MMP-1 might not be as directly 
important for proliferation but serves as a survival factor when 
GBM cells are introduced to or sense the non-permissive host 
setting, which is not replicated in vitro. 
Following demonstration that GBM cell tumorigenicity was 
significantly enhanced by the presence of MMP-1, the impact of 
this enzyme upon the other GBM pathology of angiogenesis was 
sought.  An in vitro model of tumor cell induced angiogenesis in 
a three-dimensional environment indicated that MMP-1 and 
especially GBM cells expressing MMP-1 were capable of inducing 
an in vitro angiogenic phenotype by extending endothelial sprout 
length and increasing sprout number.  Subsequently, excised 
tumors from the in vivo tumorigenicity experiments were assayed 
for reactivity with a host specific endothelial factor, CD31, 
and subjected to quantitative IHC analysis, which revealed a 
marked increase in nascent endothelium within tumors, further 
indicating a pro-angiogenic role for MMP-1.   
Only recently has MMP-1 been suggested to fulfill a pro-
angiogenic function.  Blackburn, Brinckerhoff and colleagues 
posit that this is, in part, through the activation of a GPCR 
  137 
known as PAR-1.  However, the interplay of other proven 
angiogenic factors remains elusive.  As such the angiogenic 
proteomic profiles of GBM cells in the context of MMP-1 
expression were examined.  Strikingly, notable changes in the 
detection of other pro-angiogenic proteins were not observed.  
However, in the absence of MMP-1 there were increases in anti-
angiogenic factor detection, the most profound of which was 
TIMP-4.  This inverse relationship with TIMP-4 was additionally 
confirmed, with immunoblot analyses, as well as its anti-
angiogenic activity in the in vitro model.  Since it is the most 
recently discovered member of its family, comparably little is 
known about TIMP-4, aside from MMP inhibition and anti-
angiogenic capabilities.  This relationship of TIMP-4 with one 
of its alleged inhibitory targets raises the intriguing question 
of whether the MMP is controlling the TIMP or vice versa, 
especially in light of TIMP-2 facilitated MMP-2 activation. 
Altogether these data confirm that MMP-1 is an important 
mediator of GBM pathology, and not just an expression phenomenon 
of these tumors.  Based upon the various processes it positively 
influences in gliomagenesis, MMP-1 is an attractive target for 
molecularly focused therapeutics.  It will be of importance to 
study various approaches for inhibiting the pathological 
activity of MMP-1, for example by means of the inhibition of 
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upstream mediators such as NO, or the direct inhibition of the 
enzyme itself. 
 
IV.2  Future Studies 
 
To date there have been few studies reporting on MMP-1 in GBM.  
Until the current work these investigations focused on 
expression patterns, where for example in Hodgson et al. (2009) 
MMP-1 was one of many conspicuously over-expressed proteins in 
GBM that came about from various array and gene copy analyses.  
Prior work from our laboratories by McCready and colleagues 
(2005) highlighted the importance of a single nucleotide 
polymorphism in the MMP-1 promoter (2G) in its association with 
GBM and ability to drastically increase MMP-1 expression.  This 
allele was shown to increase the sensitivity of the MMP-1 
promoter to the MAPK signal transduction pathways by introducing 
a secondary Ras Responsive Element.  This provided further 
illustration, since Rutter et al. (1998), of the importance of 
the ETS and activator protein (AP) families of transcription 
factors in mediating MMP-1 transcription.  Stojic and colleagues 
(2008) were able to confirm the expression observations of 
McCready where there was no detectable MMP-1 transcript in 
either normal brain or low-grade astrocytoma.  They were the 
first to correlate MMP-1 with the WHO grading of astrocytomas, 
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GBM having the highest mRNA and protein expressions over any 
lower grade samples. 
 The current work is the first to examine the function of 
MMP-1 in the context of GBM.  Based upon the results of the 
studies within this thesis and the prior expression studies of 
others, one can construct the general mechanistic pathways 
outlined in Figure 4.1.  It becomes clear that while our 
knowledge of MMP-1 expression and function has improved over the 
past decade, there are still a number of basic scientific 
questions that require exploration. 
 First with regard to the control of expression of MMP-1, 
while it is well established through the works of the 
Brinckerhoff, Fillmore, and Esumi (who studied NO stimulation of 
p38 and ERK) laboratories that the MAPK pathway is the prime 
mediator behind MMP-1 expression, it is still unknown which ETS 
family members are responsible in any cancer condition.  Several 
investigators have reported on this issue, and note that a 
continuing burden of limited antibody use must be overcome for 
efficacious chromatin immunoprecipitation and electrophoretic 
mobility shift assays to proceed.  It has been shown from these 
investigations however, that there are various ETS transcription 
factors highly expressed in neoplastic tissue, which is fitting 
to the model that Brinckerhoff posits, and with which McCready 
concurs: that the MMP-1 promoter is at-the-  
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Figure 4.1.  Theoretical pathways of MMP-1 significance in 
glioblastoma cells.  It is known through the work of multiple 
investigators that MMP-1 expression is particularly dependent 
upon the activity of MAPK pathways.  McCready et al. confirmed 
an enhanced expression with the introduction of an additional 
ras responsive element in GBM cells.  Ishii et al. (2003) 
demonstrated that NO can induce the activity of p38 and ERK 
kinases (MAPK) leading to downstream induction of MMP-1 
transcription in melanoma.  It appears that MMP-1 can somehow 
ease anti-angiogenic factors such as TIMP-4, CXCL4, and 
Endostatin, by unknown mechanisms.  However, it is also possible 
that MMP-1 could be directly pro-angiogenic and mitogenic 
through the activation of PAR-1 and the release of ECM-
sequestered growth factors. 
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ready in cancer, but requires the aberrant activation of its 
constituent transcription factors. Furthermore, repression of 
MMP-1 transcription by p53, presumably by interfering with other 
transcription factors (Sun et al., 1999) has elicited interest 
and is under investigation in our laboratories, especially in 
the context of ‘gain-of-function’ mutant p53 isoforms. 
Nitric oxide, with its source enzymes correlated with 
increasing glioma grade as discussed in chapter 1, and 
functional impact (chapter 2), is likely one of the factors 
responsible for an increased presence of MMP-1 in GBM.  
Therapeutics related to NO remain attractive (discussed in the 
following section), specifically because of the number of NOS 
inhibitors available, but as with the elusive ETS transcription 
factors, the relevant technology for better understanding NO in 
GBM is limited.  It is still unknown precisely how much NO 
circulates in these tumors, and there is scant evidence 
regarding NOS activity.  Nitric oxide is notoriously difficult 
to work with because of its short lifetime.  Indeed, seeking an 
effective methodology for tissue detection of NO has evolved 
into a field unto itself, and seeking answers in regard to GBM 
will require extensive collaboration with NO physiologists, and 
the development of stable NO probes for the CNS. 
Beyond expression concerns, the matter of NO emphasizes the 
importance of studying MMP-1 activity.  As mentioned previously, 
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in a seminal study Gu and colleagues (2002) demonstrated the 
permanent activation of MMP-9 through a high-NO-concentration 
dependent post-translational mechanism termed S-nitrosylation.  
Specifically, complete removal of the MMP-9 pro-domain was 
facilitated by S-nitrosylation of the conserved, critical 
‘cysteine switch.’  Such a prospect in MMP-1 is enticing.  
Efforts of this author to identify S-nitrosylation of MMP-1 
proved fruitless, but do not preclude the possibility, as just 
the detection of S-nitrosylation remains a contentious issue.  
While this offers an interesting proteomic theory, the high 
levels of NO needed to consistently S-nitrosylate pro-MMPs might 
not be locally sustained in GBM, which again highlights the 
importance of NO detection first. 
An additional interesting finding from Stojic et al. (2008) 
was the detection of MMP-1 in GBM tissue at a molecular weight 
consistent with active enzyme (42kDa) concomitant with pro-MMP-1 
(52kDa).  When lysates from tumors grown in vivo in this work 
were analyzed (Figure 3.2) immunoreactivity was suggestive of 
the active species of MMP-1, which could account for the lack of 
impact upon glioma cell growth in vitro, yet significant 
increases in tumorigenicity in vivo.  Targeting the active 
enzyme through hydroxamate zinc chelation has governed the past 
research of MMP therapy (discussed in IV.4).  Determining the 
impact on pathological function due to relative levels of active 
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MMP-1 is an important aspect for future investigation.  To 
concretely explore this prospect an effective activity assay 
will need to be applied.  Several vendors offer sensitive FRET 
based substrate assays, however these are not specific to MMP-1 
when assessing tissue specimens.  Blackburn et al. (2007) 
described an interesting in vitro collagen gel based evaluation, 
where gel weight before and after the application of active MMP 
is assessed.  The implementation of such an assay to activated 
MMP-1 over-expressers could provide preliminary insights. 
An exciting finding in this work was the functional 
implication of MMP-1 expression on GBM cell-induced 
angiogenesis.  How is this happening?  To the author, this is 
the most intriguing basic scientific question.  As detailed 
earlier (chapters 1 and 3), the Brinckerhoff laboratory is 
currently working toward a model where MMP-1 activates the pro-
angiogenic receptor PAR-1.  An unexpected finding through the 
proteomic arrays in chapter 3 was that none of the included pro-
angiogenic factors were reliably altered with respect to the 
status of MMP-1 expression.  Instead, anti-angiogenic factors 
appeared to be stimulated in the absence of MMP-1, more 
surprising was the degree to which this disposition was true 
with TIMP-4, a traditional MMP inhibitor.  As the newest member 
of the TIMP family, there is little functional data available 
for TIMP-4.  What seems to be certain is that it is anti-
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angiogenic (chapter 3; Aplin et al., 2009), yet the mechanism 
for this activity is unknown.  The potential abilities of TIMP-4 
are largely assumed based upon other TIMPS, but for example, 
TIMP-2 is well known to facilitate the activation of MMP-2.  
Therefore, such assumptions are not tenable.  It would be 
valuable to continue studies examining the expression of TIMP-4, 
especially in patient GBM samples, in a more extensive, rigorous 
manner.  To date, Groft and colleagues (2001) provide the only 
report of TIMP-4 in glioma; mRNA expression was examined in 
eight tumors, only two of which were high-grade.  Their data 
suggests that TIMP-4 expression correlates negatively with tumor 
grade, but requires further validation and functional 
investigation.  Techniques similar to those used herein – stable 
over-expression and knock-down – could provide the tools 
necessary to gain more insight into the role of TIMP-4, 
certainly in light of its relationship with the MMPs.   
The final question would be one of how MMP-1 can affect 
TIMP-4 expression.  The data presented in chapter 3 suggest that 
MMP-1 could be inhibitory toward anti-angiogenic factors.  One 
might hypothesize that a direct interaction between the two 
proteins not only inhibits further MMP-1 activity, but also 
negates TIMP-4 anti-angiogenic activity.  However in the face of 
the expression data in chapter 3, a direct post-translational 
event acting upon TIMP-4 seems unlikely.  Could MMP-1 be active 
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intracellularly to influence TIMP-4?  Supportive literature for 
such a hypothesis is certainly available.  The activation of the 
MT-MMPs and MMP-11 and -27 through furin cleavage has been 
observed within the cell (Hockenbery, 2006).  Si-Tayeb and 
colleagues (2006) reported the potential for MMP-3 to localize 
to the nucleus; Kwan et al. (2004) demonstrated this for MMP-2, 
which could also cleave PARP.  In fact a relevant investigation 
proffered by Limb and coworkers (2005) illustrates in vitro the 
capability of MMP-1 to localize to the mitochondria, and 
potentially provide resistance to apoptosis by preventing lamin 
A degradation and caspase activation.  Exploring intracellular 
possibilities with MMP-1 in GBM cells might provide information 
on this paradoxical MMP-TIMP relationship. 
IV.3  The State of NO Targeting in Cancer Therapeutics 
 
The roles of NO production in cancer pathophysiology are rather 
paradoxical and as such methods for exploiting NO or its parent 
enzymes the NOS remain one of the most hotly debated subjects in 
cancer research.  It is now generally accepted that the 
observably dichotomous effects of NO are concentration 
dependent.  In general lower levels of NO, less than micromolar, 
are tumorigenic while higher concentrations are tumoricidal.  
Early studies into the prospects of NOS inhibition in cancer 
were focused on the anti-angiogenic potential, as well as 
reduction of tumor specific blood circulation.  In the melanoma 
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and adenocarcinoma settings, the same arginine analog (L-NAME) 
used in the aforementioned sections selectively inhibited tumor 
blood flow (Andrade et al., 1992).  This was later replicated in 
rats harboring P22 carcinosarcomas (Tozer et al., 1997).  This 
effect was reversible in all cases with the administration of L-
arginine, the substrate for NOS activity.  Furthermore there was 
a marked dose-dependence, that once the optimal dose of NOS 
inhibitor was surpassed, no further reduction in tumor blood 
flow was seen.  This is attributable to one of the problems with 
the systemic administration of NOS inhibitors: increase in mean 
arterial blood pressure, i.e. hypertension. 
 Closer examination of the impact of L-NAME administration 
with the goal of restricting tumor induced nutrient flow showed 
that the inhibitor can act synergistically with other anti-tumor 
treatments such as melphalan, TNF-α, and IL-2 (Orucevic and 
Lala, 1996; de Wilt et al., 2000).  Both of these works were 
conducted in adenocarcinoma models, where Orucevic and Lala 
present data that the inhibition of NO production assists IL-2 
mediated toxicity.  The production of anti-tumoral lymphokine-
activated killer cells (LAK) is assisted by IL-2; normally, NO 
inhibits the proliferation and activity of LAKs, and thus NOS 
inhibition improved IL-2 mediated tumor resolution.  In a later 
elegant study, Okada and colleagues (2006) observed a vital role 
for NO in cancer progression.  Benign murine fibrosarcoma cells 
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were grown in vivo in gelatin sponge grafts (to induce an 
inflammatory response).  An iNOS specific inhibitor, 
aminoguanidine (AG), was systemically administered through 
drinking water to the experimental arm of the study.  Tumors +/- 
AG treatment were harvested, homogenized, and intravenously 
administered to syngeneic mice to assess metastatic potential.  
Both the incidence of metastasis and number of metastatic 
nodules in the lungs of mice with AG treated tumors were 
substantially reduced, indicating that NO was vital to the 
malignant transformation of this tumor type.  Metastatic, 
tumorigenic, invasive, and motile potentials of NO are supported 
by these studies, Ishii and coworkers (2003) showing the 
induction of specific MMPs in melanoma, and the present work 
demonstrating the pathological contributions of MMP-1 in 
glioblastoma. 
 Despite the clear evidence that NO, at levels presumably 
produced by a tumor and through the use of NOS inhibitors, is a 
tumorigenic molecule, there remains a substantial force in 
research for the use of excessively high concentrations of NO 
and its related nitrosative stress products, e.g. peroxynitrite, 
as tumoricidal agents.  One such suggestion has been through the 
lens of bioreductive chemotherapeutics.  These drugs target 
hypoxic tumor areas where they are reduced into cytotoxic 
metabolites.  In the context of iNOS over-expression, it has 
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been shown that the DNA damage induction of at least one of 
these drugs, Tirapazamine, is potentiated presumably by P450 
reductase, to which the NOS enzyme structures are similar 
(Saunders et al., 2000; Chinje et al., 2003).  While the use of 
hypoxia targeting chemotherapeutics is useful, especially 
considering recent evidence supporting the HIF-2α axis in 
multiple human cancers (Franovic et al., 2009), the relevance of 
these drugs to NO in highly invasive, oxic cancer cells, such as 
in the periphery of glioblastoma, is not concrete. 
 Most approaches to using high levels of NO as a treatment 
involve the systemic delivery of NO donors.  However, unlike the 
NOS inhibitors which have shown significant and specific anti-
tumoral effects at less than systemically detrimental doses as 
aforementioned, the therapeutically meaningful doses of NO 
required from most donors in a glioblastoma setting are 
impracticably high, i.e. on the order of hundreds of micromolar 
to tens of millimolar (Weyerbrock et al., 2009).  This produces 
the immediate and obviously life threatening effect of profound 
hypotension (Abrams, 1992) before mechanisms of cytotoxicity, 
which require temporally extensive administration, can even 
become manifest.  Attempts have been made to circumvent this 
issue, such as the indirect activation of iNOS through IFN-γ, or 
iNOS based, hypoxia driven gene therapies, but the extensive 
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side effects or low efficiencies of these approaches has limited 
continued investigation (Fitzpatrick et al., 2008). 
IV.4 The State of MMP Targeting in Cancer Therapeutics 
 
The by and large agreement in the literature that a number of 
the MMPs are integral to tumor cell migration, invasion, and 
metastasis made them attractive targets for direct inhibition 
starting in the 1990’s.  An early inhibitor known as batimastat 
(BB-94) is a synthetic peptide that mimics a collagen cleavage 
site, thus making it a broad spectrum MMP inhibitor.  Its 
inhibition is dependent upon a hydroxamate moiety that chelates 
the MMP active site zinc atom, thus blocking hydrolysis, however 
the details regarding molecular interactions behind hydroxamate-
inhibitor specificity remain incomplete (Brown and Giavazzi, 
1995; Jani M et al., 2005). The use of this inhibitor has shown 
a reduction in metastatic tumor burden in murine melanoma 
models, but no cytotoxic impact (Chirivi et al., 1994; Brown and 
Giavazzi, 1995).  Furthermore, the progression of human ovarian 
and colorectal carcinomas as well as murine hemangioma growth 
and angiogenesis were inhibited (Brown and Giavazzi, 1995). 
 Batimastat was taken to phases I and II clinical trials, 
and subsequently it was discovered that oral dosage of the drug 
did not allow efficacious bioavailability.  Intraperitoneal 
administration was required to have noticeable effect, however 
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this method is an undesirable treatment modality (Brown and 
Giavazzi, 1995; Wojtowicz-Praga et al., 1997).  Therefore, a 
second generation of MMP inhibitors with oral bioavailability 
was produced, of which one known as marimastat (BB-2516) was 
championed.  It too is a collagen-like peptidomimetic with a 
zinc-chelating hydroxamate.  It was reported to have specific 
activities against MMPs-1, -2, -3, -7, and -9, especially MMPs-1 
and -9 (Wojtowicz-Praga et al., 1997).  Pre-clinical results for 
the use of marimastat were similar to those of its predecessor 
(Wojtowicz-Praga et al., 1998).  Additionally, studies were 
conducted describing significant reductions in glioblastoma cell 
invasion and in vitro tumor growth with both hydroxamate-based 
inhibitors.  This effect was evaluated for impacts on cell 
viability and it was observed (again for batimastat but with 
novelty for marimastat) that the anti-tumor activity of these 
drugs was predominantly through cytostatic, not cytotoxic, 
mechanisms, which made marimastat an even more promising drug 
candidate in the context of preserving host CNS tissue (Tonn et 
al., 1999).   
 However, the enthusiasm for the second generation MMP 
inhibitor soon began diminishing.  A phase I trial in advanced 
lung cancer patients demonstrated the oral efficacy of 
marimastat delivery through the gut, however a dose limiting 
inflammatory polyarthrits toxicity was observed, which had a 
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cumulative effect because of lingering plasma drug 
concentrations.  Since plasma concentrations that replicated the 
in vitro anti-tumoral effects of marimastat were achievable at 
low oral dosage it was recommended that its use be further 
investigated (Wojtowicz-Praga et al., 1998).  A phase II study 
of marimastat plus temozolomide in recurrent GBM patients showed 
a progression free survival benefit.  However nearly half of the 
patients experienced drug-induced arthritis, most often in hand 
joints, and the study population was too small for any rigorous 
statistical evaluation (Groves et al., 2002).  Other human data, 
especially in metastatic breast cancer patients, practically 
removed marimastat from anti-cancer consideration.  A prominent 
phase II trial showed that marimastat did not extend progression 
free survival in breast cancer patients, but rather elicited the 
same musculoskeletal toxicities mentioned before, which were 
actually associated with reduced survival (Sparano et al., 
2004).  These data in combination with a perceived ill-placed 
pre-clinical optimism for batimastat and marimastat led to 
pariah status and eventual downfall of the drugs’ patents holder 
British Biotech.  More extensive clinical data regarding the use 
of marimastat in glioma were slower to evolve, but did not offer 
any enthusiastic results, where no benefit over temozolomide 
alone was observed in recurrent anaplastic astrocytoma (Groves 
et al., 2006), and in a larger double-blind, placebo controlled 
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GBM study, no progression free survival benefit was recorded 
(Levin et al., 2006). 
 Despite this hit to the study of MMPs in cancer 
pathophysiology, there remain other promising targeting avenues.  
Another hydroxamate-based inhibitor, prinomastat (AG3340), 
demonstrates particular selectivity for the MT1-MMP mediated 
invasion axis (Scatena, 2000).  It also shows potency toward MMP 
-13, another collagenase recently found over-expressed in 
malignant glioma.  Indeed, comparably little work has been 
published regarding prinomastat, likely because of the distaste 
associated with hydroxamate MMP inhibitors, but one extensive 
pre-clinical study reported profound inhibition of GBM cell 
proliferation, in vivo tumor growth (s.c. model), and a long 
lasting, host-positive effect (Price et al., 1999).  A clinical 
pharmacokinetic study of this inhibitor in multiple advanced 
stage cancers found that it could elicit the same undesirable 
side effects of its hydroxamate predecessors, but these issues 
were only seen with excessive dosing while lower doses achieved 
desirable plasma concentrations without deleterious side effects 
(Hande et al., 2004).  However, a subsequent phase III study 
reported no chemotherapeutic benefit with prinomastat in NSCLC 
(Bissett et al., 2005).  However, as mentioned earlier in this 
work (Chapter 1) at least with regard to EGFR therapies, there 
are considerable differences in effectiveness of treatment 
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modalities between NSCLC and GBM.  A phase II GBM study was 
completed in 2002, however the results have yet to be reported, 
and presumably its use in GBM is still under investigation 
(Adamson et al., 2009).  
 Naturally occurring macrocyclic lactides have also been 
proposed for investigation in malignant gliomas (da Rocha et 
al., 2002).  Bryostatin-1 is a compound of specific interest, 
which is isolated from the larvae of Bugula neritina, a marine 
bryozoan.  This compound has been shown to induce the 
differentiation of cancer cells in vitro by activating protein 
kinase C (PKC) after early exposure, while eventually leading to 
a reduction in the kinase, which notably inhibits the production 
of MMPs-1, -3, -9, -10, and -11 but does not alter their 
activities (Wojtowicz-Praga et al. 1997; Johnson et al., 1999).  
Recent clinical data using bryostatin-1 as a specific agent show 
mixed, tumor specific responses.  For example, Lam and 
colleagues (2009) report that the combination of bryostatin-1 
and paclitaxel is not an effective paradigm for advanced 
pancreatic carcinoma.  However, Barr and coworkers (2009) 
observed efficacy in certain cases of aggressive B-cell non-
Hodgkin lymphoma.  It has been noted by both investigators that 
newer, more effective and specific ‘bryologs’ are in development 
that might show improvements upon bryostatin-1 in the clinic.  
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The potential for bryostatin-1 and its analogs remains to be 
studied in GBM and many cancer conditions altogether. 
 The toll-like receptor 9 (TLR9) sub-family of TLRs are 
intracellular components of the immune system.  The traditional 
ligands of TLR9 are unmethylated CpG areas of microbial nucleic 
acids.  Binding and activation of these receptors is commonly 
described as leading to the production of various inflammatory 
cytokines (Wagner, 2004). Recalling the promoter structures of 
the MMPs described in Chapter 1, it is reasonable to theorize 
that the downstream transcription factors up-regulated by TLR9 
activity, such as NfκB, could also target and elicit MMP gene 
transcription.  Merrell and colleagues (2006) described MMP-
dependent induction of invasion by TLR9 CpG-oligonucleotide 
(ODN) agonists.  These compounds mimic the microbial ligands of 
TLR9, thereby causing their activation. The use of another MMP 
inhibitor, ilomastat (GM6001), or MMP-13 specific antibodies 
abrogated CpG-ODN instigated invasion in GBM and breast cancer 
cell lines.  More recent work by Meng et al. (2008) describes 
the expression of TLR9 in patient GBM samples as largely immune 
cell localized, in agreement with Merrell’s assertion that 
infectious responses by immune system components might 
contribute to cancer progression. 
 Finally, the excitement surrounding anti-angiogenic 
therapies for GBM, specifically bevacizumab, brings to light 
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once again the importance of MMPs.  A current publication 
presents evidence that the treatment of GBM cells with 
bevacizumab alters the expression of several of these enzymes.  
The expression characteristics are not the same across MMPs, 
where MMPs-2, -9, and -12 were stimulated by bevacizumab, and 
interestingly educed a 25-fold reduction in MMP-1.  Furthermore, 
it was posited that bevacizumab resistant cells utilize over-
expression of at least MMPs-2, -9, and -12 as well as TIMP-1 to 
subvert the therapy (Lucio-Eterovic et al., 2009).  These 
findings, especially the implication of TIMP-1, are especially 
prescient in light of this body of work.   
 
IV.5  Concluding Remarks 
 
Glioblastoma multiforme has evaded the best-focused efforts of 
neuro-oncologists for decades.  While it is a relatively 
uncommon cancer, diagnosis with GBM is, with near certainty, a 
fast-attacking, terminal disease.  Few other conditions can have 
as an immediately detrimental and seemingly helpless impact in 
the manner that GBM can.  Notwithstanding this dire history 
there have been some steps in treating GBM.  The front-line 
effort of tumor de-bulking has vastly improved with 
neurosurgical techniques, equipment, and thinking with a firm 
emphasis on removing as much of a primary tumor mass as 
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possible.  Newer imaging techniques, for example through the use 
of metallofullerene caged contrast enhancement agents currently 
under investigation in our laboratories, have a strong potential 
to assist neurosurgeons in more confidently achieving the 
greatest possible extent of resection.  In addition, radiation 
therapy modalities and temporal paradigms have been focused and 
optimized over the years and now work in concert with 
chemotherapeutics such as BCNU and temozolomide to improve 
median survival. 
 However, gone are the days of the exclusive use of grossly 
non-specific therapies.  Molecular targeted therapeutics is the 
new front of treating this and other diseases.  With the 
improvements in tools, and knowledge, e.g. genomes, and 
proteomes, and experience, efforts attacking specific genes and 
proteins offer promising avenues for combinatorial therapies.  
The swift evolution of anti-VEGF therapies in addition to 
traditional modalities in multiple advanced cancers including 
GBM is a prime example of this movement.  Many clinicians and 
researchers, including this author, envision a not-so-distant 
future when many afflictions like GBM will have individual 
patient tailored remedies and specifically targeted drug 
approaches. 
 The field of MMP research in cancer undoubtedly suffered 
from disappointing inhibitor studies at the turn of the 20th and 
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21st centuries.   However, these inhibitors were based on a 
singular (collagen mimetic, hydroxamate) approach, with a lesser 
understanding of how MMPs were controlled.  Today we know a 
great deal more about specific MMPs with regard to certain 
conditions, as presented for instance in this work, and 
potential upstream and downstream regulators and effects.  
Control of NO is one such promising path considering the 
preponderance of cNOS expression in high-grade tumors, and the 
availability of a plethora of NOS inhibitors.  However, this 
will not be the only approach.  Investigations are ongoing with 
regard to upstream and downstream regulation of MMP-1, for 
example the activation of PAR-1.  Finally, it is the opinion of 
this author that it might be possible for the direct inhibition 
of MMPs in cancer to return to light.  This will require the 
collaborative efforts of clinicians, pharmacologists, molecular, 
and structural biologists to discover effective small molecule 
or antibody therapies to combat this grim affliction. 
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Appendix A.  Glioma Cell Scratch Motility Test 
Purpose: To assess the No-induced motility of glioma cells. 
Method:  U-87 MG cells were passaged into 100mm diameter cell 
culture dishes at a density of 1.5x106 cells per dish.  Dishes 
were divided between two conditions – either control (normal 
culture conditions as described in Chapter 2) or with 100µM SNP.  
The cells were allowed to settle and acclimate overnight.  The 
next morning media were changed and three scratches were made in 
each dish using a 200µL pipette tip made for Rainin LTS 
pipettors.  Images were immediately taken at 200x magnification 
phase contrast at three points along each scratch as a zero hour 
time point.  Subsequent images were captured three and six hours 
later.  The experiment was repeated thrice.  ImageJ was 
calibrated to the appropriate magnification and utilized to 
calculate the area of scratches in square microns.  Data are 
reported as percent decrease in scratch area. 
Results: The inclusion of SNP in culture media significantly 
increased scratch closure by 16% (p<0.01) at the three-hour time 
point (figure A.1).  Cells traversed scratches regardless of SNP 
by the six-hour time point.  This type of experiment confirms 
the findings of the membrane based invasion assay.  It should be 
noted that two of the major differences are: this assay requires 
nearly 100% confluence, and it is two-dimensional, whereas the 
membrane based assays test cells along a vertical axis. 
  196 
A.1 
 
 
 
 
 
 
 
  197 
Appendix B: pIRES and pLKO.1 vector maps 
Since the alteration of MMP-1 for extended periods of time was 
an objective in Chapter 3 with the in vivo tumor growth and the 
in vitro angiogenesis assays, stable transfections were needed.  
Furthermore, while in theory transient transfections could have 
sufficed for the in vitro angiogenesis experiments, the stress 
of transient transfection methods, combined with the elaborate 
conditions of three-dimensional culture would likely have 
confounded the results.  Finally, the consistency of using the 
same, pooled clones for the in vivo experiments was ideal.  A 
standard cDNA system was utilized for the over-expression MMP-1; 
the first figure (B.1) is a map of the pIRES vector developed by 
the VCU-Massey Cancer Center Molecular Biology Core Facilities, 
which elicits forced expression of MMP-1 under the CMV promoter 
and can be stably selected for via neomycin (G418) resistance 
(map provided by Monika Anand).  For the knock-down of MMP-1 
production, a lentiviral system (second figure, B.2, modified 
from the Sigma MISSION® shRNA literature library) was chosen, 
where stable clones could be selected via puromycin resistance.  
Specific lentiviral particles were utilized containing sequences 
used for naked MMP-1 siRNA in the Chapter 2 methods. 
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Appendix C: Angiogenesis Antibody Array Summary 
Whole representative, developed angiogenesis antibody arrays 
that were used in Chapter 3 for T98G cells are displayed in 
figure C.1; arrows indicate the location of TIMP-4 
immunodetection.  Table C.2 is a summary of percent change in 
the MMP-1 knockdown group compared to control. Figure C.3 is a 
graphical representation of notable changes other than TIMP-4.  
It should be noted that immunodetection for ADAMST-1 was low and 
variable across repetition, and that none of the changes seen in 
any other proteins approached the order of magnitude and 
consistency to which TIMP-4 is altered.  The dark spots in the 
corners of each array are positive controls for loading. 
 Figure C.4 shows an angiogenesis antibody array conducted 
using pooled U251 controls and over-expressers.  The differences 
in proteomic profiles between the two cell lines are apparent, 
as U251 expresses far fewer angiogenesis related proteins.  
Unlike T98G, U251 does not normally express MMP-1, or TIMP-4 as 
can be seen in C.4.  These data lend evidence to a complex 
balance between pro- and anti-angiogenic forces, of which MMP-
1/TIMP-4 are parts.  Differences that were detected with forced 
MMP-1 expression were minor in comparison to T98G TIMP-4 data, 
failing to achieve fold changes; effective antibodies for 
confirmatory immunoblots will be needed for future studies. 
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Table C.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name % Change 
Artemin -54.96 
MMP-8 -52.09 
FGF-4 -50.49 
DPPIV -48.91 
MCP-1 -44.84 
Angiostatin/Plasminogen -42.91 
Coagulation Factor III -42.36 
IL-1B -38.07 
Endothelin-1 -38.02 
CXCL16 -37.07 
FGF-7 -34.32 
PDGF-AA -30.08 
Serpin B5 -26.51 
PlGF -26.36 
Angiopoietin-2 -26.35 
Leptin -26.20 
VEGF -24.57 
VEGF-C -22.37 
Vasohibin -21.68 
Endostatin/CollagenXVIII -21.37 
TGF-B1 -18.59 
IGFBP-3 -17.43 
MIP-1a -13.58 
Platelet Factor 4 -7.81 
MMP-9 -6.04 
Serpin F1 -4.81 
TIMP-1 -0.41 
Prolactin 0.71 
Name % Change 
GDNF 1.49 
HGF 3.51 
PD-ECGF 4.19 
Angiopoietin-1 6.63 
IL-8 7.13 
HB-EGF 7.24 
Persephin 7.69 
FGF basic 9.69 
EGF 12.36 
Amphiregulin 17.08 
Serpin E1 20.09 
uPA 26.45 
IGFBP-2 28.79 
PDGF-AB/PDGF-BB 30.23 
Angiogenin 31.07 
GM-CSF 35.01 
Thrombospondin-2 42.52 
Endoglin 45.47 
NRG1-B1 52.51 
Activin A 57.27 
IGFBP-1 62.96 
Thrombospondin-1 70.92 
EG-VEGF 80.87 
FGF acidic 83.80 
Pentraxin 3 106.72 
ADAMTS-1 199.49 
TIMP-4 1138.83 
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Arrows denote the locations of the TIMP-4 antibody spots.  
Noticeable changes included a reduction in the detections of 
endostatin (anti-angiogenic) and bFGF (angiogenic) with forced 
MMP-1 expression. 
  205 
Appendix D: P-Kinase Antibody Array Summary 
In an effort to assist future studies in identifying possible 
cell signaling factors sensitive to MMP-1 expression, antibody 
arrays (ARY003, R & D Systems) spotted against a limited number 
of phospho-kinases, i.e. active kinases, were conducted. These 
arrays were performed according to the manufacturer’s protocol, 
and lysates collected as described in Chapter 3 Methods.  Figure 
D.1 displays representative T98G arrays.  Table D.2 is a summary 
in the same fashion as table C.2, and figure D.3 is a graphical 
representation.  The most consistent change in T98G MMP-1 knock-
down lysates was an increased activation of Akt at threonine 
308, denoted by asterisks in figure D.1; otherwise noted changes 
were for the most part subtle in terms of immunoreactivity and 
variable across repetitions. 
 Figure D.4 displays U251 P-kinase arrays.  The most notable 
differences were decreases in all phospho-p53 (three pairs of 
descending spots below the black arrows in D.4) and p-CREB (‘+’ 
on the left side of the arrays).  Interestingly there were 
converse changes in detection such as with β-catenin and CREB 
increasing with MMP-1 knockdown in T98G (Figure D.3), and 
decreasing with MMP-1 over-expression (Figure D.6).  However, 
caution should again be exercised, as all these differences are 
subtle in the context of the control spots (again, the 
immunoreactive spots in the corners of the arrays).  These data 
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remain inconclusive and are currently, in part, under 
investigation by Anand and colleagues.   
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Table D.2. T98G p-kinase antibody arrays 
 
 
Name % Change 
STAT5a/b -26.77 
STAT5b -25.71 
c-Jun -17.21 
STAT3 -16.920 
MEK1/2 -14.97 
Hck -9.43 
p27(T198) -7.42 
Paxillin -5.41 
STAT6 -5.15 
p27(T157) -5.09 
ERK1/2 -4.34 
Lyn 4.35 
Fyn 4.37 
AMPKa2 5.32 
MSK1/2 8.13 
Chk-2 8.19 
JNK pan 8.47 
p53(S46) 8.61 
p53(S392) 8.83 
Yes 10.87 
p53(S15) 10.98 
PLCg-1 12.42 
STAT2 13.26 
Name % Change 
p70 S6 Kinase(T389) 15.01 
Src 16.96 
Pyk2 17.84 
p70 S6 Kinase(T421/S424) 18.82 
Akt (s473) 19.943 
FAK 21.18 
STAT1 22.43 
p70 S6 Kinase(T229) 22.84 
eNOS 23.39 
GSK3a/b 25.29 
TOR 29.65 
STAT4 29.83 
RSK1/2(S221) 36.72 
CREB 37.94 
AMPKa1 42.58 
p38alpha 42.96 
B-catenin 50.11 
Lck 50.57 
RSK1/2/3(S380) 52.97 
STAT5a 57.19 
Akt(T308) 62.93 
HSP27 65.23 
Fgr 68.72 
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Table D.5. U251 p-kinase antibody arrays 
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